EP0819013B1 - System for performing endovascular procedures - Google Patents

System for performing endovascular procedures Download PDF

Info

Publication number
EP0819013B1
EP0819013B1 EP96908744A EP96908744A EP0819013B1 EP 0819013 B1 EP0819013 B1 EP 0819013B1 EP 96908744 A EP96908744 A EP 96908744A EP 96908744 A EP96908744 A EP 96908744A EP 0819013 B1 EP0819013 B1 EP 0819013B1
Authority
EP
European Patent Office
Prior art keywords
catheter
patient
lumen
shaft
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96908744A
Other languages
German (de)
French (fr)
Other versions
EP0819013A1 (en
EP0819013A4 (en
Inventor
John H. Stevens
William S. Peters
Wesley D. Sterman
Hansen S. Gifford, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edwards Lifesciences AG
Original Assignee
Heartport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heartport Inc filed Critical Heartport Inc
Publication of EP0819013A1 publication Critical patent/EP0819013A1/en
Publication of EP0819013A4 publication Critical patent/EP0819013A4/en
Application granted granted Critical
Publication of EP0819013B1 publication Critical patent/EP0819013B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/1011Multiple balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0021Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0041Catheters; Hollow probes characterised by the form of the tubing pre-formed, e.g. specially adapted to fit with the anatomy of body channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/0105Steering means as part of the catheter or advancing means; Markers for positioning
    • A61M25/0133Tip steering devices
    • A61M2025/0161Tip steering devices wherein the distal tips have two or more deflection regions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/0105Steering means as part of the catheter or advancing means; Markers for positioning
    • A61M25/0133Tip steering devices
    • A61M25/0152Tip steering devices with pre-shaped mechanisms, e.g. pre-shaped stylets or pre-shaped outer tubes

Definitions

  • the present invention relates generally to devices for performing diagnostic or therapeutic endovascular procedures within the circulatory system of a patient. More particularly, it relates to a system for isolating the heart and coronary blood vessels of a patient from the remainder of the arterial system, for inducing cardioplegic arrest in the heart and for performing diagnostic or therapeutic endovascular procedures within the heart or blood vessels of the patient while the heart is stopped.
  • a system according to the preamble of claim 1 is known from EP-A-0 604 803.
  • the surgical procedure is carried out using instruments that operate through the intercostal penetrations while the heart is stopped using the endoaortic catheter.
  • Another surgical approach presented in the parent applications is an endovascular approach, in which diagnostic or therapeutic endovascular devices are inserted through a lumen in the endoaortic catheter to carry out an endovascular procedure within the heart or blood vessels of the patient.
  • the present invention addresses the endovascular surgical approach and the endovascular procedures that can be carried out using the endoaortic catheter.
  • WO95/08364 discloses an endovascular device for partitioning the ascending aorta and a system for arresting the heart to facilitate the performance of procedures such as heart valve replacement.
  • the present invention provides a system according to claim 1.
  • the invention may thus allow the combination of diagnostic and therapeutic endovascular procedures with cariopulmonary bypass and carioplegic arrest in a manner that facilitates rather than inhibits the performance of both procedures. That is to say that the isolation of the heart and its blood vessels necessary for cardioplegia and cardiopulmonary support can be accomplished entirely through endovascular means without the necessity of a gross thoracotomy, and that, simultaneously, a path is created for introduction for one or more devices for performing a diagnostic or therapeutic endovascular procedure.
  • Endovascular procedures which lend themselves to this approach include diagnostic procedures, such as electrophysiological mapping of the heart or ablation of electrophysiological structures within the heart.
  • the present invention may take the form of a system that includes an endoaortic catheter for inducing cardioplegic arrest in the heart of a patient and at least one endovascular device which is slidably received within a lumen of the endoaortic catheter for performing an endovascular procedure on the patient's heart.
  • a cardiopulmonary bypass (CPB) system such as a femoral-femoral CPB system, may be used in conjunction with the endoaortic catheter for supporting the systemic circulation of the patient while the heart is stopped.
  • the endovascular procedure can be performed as the sole procedure on the patient or it can be performed in conjunction with another cardiac surgical procedure, such as a port-access CABG procedure or heart valve replacement procedure, as described in the parent cases.
  • the endovascular procedure can be carried out on the patient's heart while it is stopped or it can be performed on the beating heart in order to reduce the time that the heart is stopped (often referred to as the crossclamp time.)
  • the endoaortic partitioning catheter which is the foundation of the system for performing endovascular procedures is introduced percutaneously or by direct cut-down through the femoral artery.
  • This catheter must carry adjacent its tip an inflatable cuff or balloon of sufficient size that upon being inflated it is able to completely occlude the ascending aorta.
  • the length of the balloon should preferably not be so long as to impede the flow of blood or other solution to the coronary arteries or to the brachiocephalic, left carotid or left subclavian arteries.
  • a balloon length of about 40 mm and diameter of about 35 mm is suitable in humans.
  • the balloon may be of a cylindrical, spherical, football-shaped or other appropriate shape to fully and evenly accommodate the lumen of the ascending aorta. This maximizes the surface area contact with the aorta, and allows for even distribution of occlusive pressure.
  • the balloon of the catheter is in fluid communication with an inflation lumen that extends the length of the catheter.
  • the balloon is preferably inflated with a saline solution to avoid the possibility of introducing into the patient an air embolism in the event that the balloon ruptured.
  • the balloon should be inflated to a pressure sufficient to prevent regurgitation of blood into the aortic root and to prevent migration of the balloon into the root whilst not being so high as to cause damage or dilation to the aortic wall.
  • the endoaortic partitioning catheter is preferably introduced under fluoroscopic guidance over a suitable guidewire.
  • Transoesophageal echocardiography can alternatively be used for positioning the aortic catheter.
  • the catheter may serve a number of separate functions and the number of lumina in the catheter will depend upon how many of those functions the catheter is to serve.
  • the catheter can be used to introduce the cardioplegic agent, normally in solution, into the aortic root via a perfusion lumen.
  • the luminal diameter will preferably be such that a flow of the order of 250-500 ml/min of cardioplegic solution can be introduced into the aortic root under positive pressure to perfuse adequately the heart by way of the coronary arteries.
  • the same lumen can, by applying negative pressure to the lumen from an outside source, effectively vent the left heart of blood or other solutions.
  • the endoaortic partitioning catheter is adapted for introduction of one or more endovascular devices through an internal lumen of the catheter.
  • This may be a separate lumen from the inflation lumen and the perfusion lumen discussed above or, for simplicity of construction and to maximize the potential lumen diameter, the perfusion lumen may be combined with the lumen for introduction of endovascular devices.
  • the diameter and cross-sectional design of the internal lumina are such that the external diameter of the catheter in its entirety is small enough to allow its introduction into the adult femoral artery by either percutaneous puncture or direct cut-down.
  • the system for performing endovascular procedures combines the endoaortic partitioning catheter with an electrophysiology mapping and ablation catheter for diagnosing and treating electrophysiological conditions of the heart.
  • endoaortic partitioning catheter with these endovascular diagnostic and therapeutic devices.
  • Introducing endovascular devices through a lumen of the endoaortic partitioning catheter allows the patient's heart to be stopped and the circulatory system supported on cardiopulmonary bypass while performing the endovascular procedure. This may allow the application of various endovascular procedures to patients whose cardiac function is highly compromised and therefore might not otherwise be good candidates for the procedure. It also allows the endovascular procedures to be performed as an adjunct to other cardiac surgical procedures.
  • the endoaortic partitioning catheter can be used as a guiding catheter for introducing an endovascular device and for performing an endovascular procedure while the patient is on partial cardiopulmonary support without inflating the occlusion balloon or inducing cardiac arrest. If and when it is desired, the endoaortic partitioning catheter can be activated to occlude the aorta and induce cardioplegia, thereby converting the patient from partial cardiopulmonary support to full cardiopulmonary bypass. This mode of operation would be advantageous when it was desired to follow the endovascular procedure with another surgical procedure on the heart using either a thoracoscopic or standard open chest approach.
  • the invention provides a system for performing endovascular procedures including an endoaortic device for partitioning the ascending aorta in combination with an endovascular device for performing a diagnostic or therapeutic endovascular procedure within the heart of a patient.
  • the system may also include a means for selectively arresting the heart, such as a means for retrograde or antegrade infusion of cardioplegic fluid for inducing cardioplegic arrest.
  • the invention is especially useful in conjunction with minimally-invasive cardiac procedures, in that it allows the heart to be arrested and the patient to be placed on cardiopulmonary bypass using only endovascular devices, obviating the need for a thoracotomy or other large incision.
  • the procedures with which the invention will find use include diagnostic procedures, such as electrophysiological mapping of the heart, and therapeutic procedures, such as, ablation of electrophysiological structures within the heart.
  • diagnostic procedures such as electrophysiological mapping of the heart
  • therapeutic procedures such as, ablation of electrophysiological structures within the heart.
  • the endovascular procedure which is performed using the system of the invention may be the primary procedure performed on the patient, or, alternatively, the endovascular procedure may be performed as an adjunct to another endovascular, thoracoscopic or open heart procedure.
  • the endovascular procedure system includes an elongated aortic occlusion or delivery catheter 10 which has an expandable member 11 on a distal portion of the catheter which, when inflated as shown, occludes the ascending aorta 12 to separate the left ventricle 13 and upstream portion of the ascending aorta from the rest of the patient's arterial system and securely positions the distal end of the catheter within the ascending aorta.
  • An endovascular device for performing a diagnostic or therapeutic procedure represented here by a valvuloplasty catheter 500 which is outside the scope of the invention, is slidably received within an internal lumen of the aortic occlusion catheter 10.
  • a cardiopulmonary bypass system 18 removes venous blood from the femoral vein 16 through the blood withdrawal catheter 17 as shown, removes CO 2 from the blood, oxygenates the blood, and then returns the oxygenated blood to the patient's femoral artery 15 through the return catheter 19 at sufficient pressure so as to flow throughout the patient's arterial system except for the portion blocked by the expanded occluding member 11 on the aortic occluding catheter 10.
  • a fluid containing cardioplegic agents can be delivered through an internal lumen of the endoaortic occluding catheter in an antegrade manner into the aortic root and into the coronary arteries to paralyze the myocardium.
  • a retrograde cardioplegia balloon catheter 20 may be placed within the patient's venous system with the distal end of the catheter extending into the coronary sinus 21 to deliver a fluid containing cardioplegic agents to the myocardium in a retrograde manner through the patient's coronary venous system to paralyze the entire myocardium.
  • the elongated occluding catheter 10 extends through the descending aorta to the left femoral artery 23 and out of the patient through a cut down 24.
  • the proximal extremity 25 of the catheter 10 which extends out of the patient is provided with a multi-arm adapter 26 with one arm 27 adapted to receive an inflation device 28.
  • the adapter 26 is also provided with a second arm 30 with main access port having a hemostasis valve 31 through which the endovascular device 500 is inserted into internal lumen of the aortic occlusion catheter 10.
  • the function of the hemostasis valve 31 may also be provided by a separate adapter which connects to second arm 30 of the multi-arm adapter 26.
  • a third arm 32 connected to bypass line 33 is provided to direct blood, irrigation fluid, and the like to or from the system.
  • a suitable valve 34 is provided to open and close the bypass line 33 and direct the fluid passing through the bypass line to a discharge line 35 or a line 36 to a blood filter and recovery unit 37.
  • a return line may be provided to return any filtered blood, which will be described hereinafter, to the cardiopulmonary bypass system 18 or other blood conservation system.
  • the catheter 10 includes an elongated catheter shaft 39 which has a first inner lumen 40 in fluid communication with the main access port 31 in the second arm of the adapter 26 and is adapted to facilitate the passage of an endovascular device, again represented by a valvuloplasty catheter 500, and out the distal port 41 in the distal end thereof.
  • a supporting coil 42 may be provided in the distal portion of the first inner lumen 40 to prevent the catheter shaft 39 from kinking and to enhance radial rigidity and to maintain the transverse dimensions of first inner lumen 40 as the catheter 10 is advanced through the aortic arch. It is particularly important to maintain the roundness of first inner lumen 40 where an endovascular device is to be introduced through the first inner lumen. If the shaft is made of sufficient diameter to accommodate such tools through lumen 40, the shaft may tend to flatten or kink when advanced into the curved region of the aortic arch.
  • the use of wire braid or coil 42 to maintain lumen roundness allows the endovascular device profile to be maximized and allows endovascular devices to be advanced through the lumen with minimum interference.
  • Wire braid or coil 42 may be formed of stainless steel or other biocompatible material such as a cobalt alloy, nickel titanium alloy, aramid fibers such as KevlarTM (DuPont), or nylon.
  • the shaft 39 is also provided with a second inner lumen 43 which is in fluid communication with the interior of the occluding balloon 11.
  • partitioning device 320 includes a shaft 322 having a distal end 324 and a proximal end 326.
  • An expandable means 328 for occluding the ascending aorta is mounted to shaft 322 near distal end 324.
  • occluding means 328 comprises a polymeric balloon 330 (shown inflated) of a material, geometry, and dimensions suitable for completely occluding the ascending aorta to block systolic and diastolic blood flow, as described more fully below.
  • Shaft 322 has a diameter suitable for introduction through a femoral or iliac artery, usually less than about 9 mm.
  • the length of shaft 322 is preferably greater than about 80 cm, usually about 90-100 cm, so as to position balloon 330 in the ascending aorta between the coronary ostia and the brachiocephalic artery with proximal end 326 disposed outside of the body, preferably from the femoral or iliac artery in the groin area.
  • the shaft may be configured for introduction through the carotid artery, through the brachial artery, or through a penetration in the aorta itself, wherein the shaft may have a length in the range of 20 to 60 cm.
  • Partitioning device 320 further includes a first inner lumen 329, extending between proximal end 326 and distal end 324 with an opening 331 at distal end 324. Additional openings in communication with inner lumen 329 may be provided on a lateral side of shaft 322 near distal end 324.
  • Shaft 322 has a shaped distal portion 332 configured to conform generally to the curvature of the aortic arch such that opening 331 at distal end 324 is spaced apart from the interior wall of the aorta and is axially aligned with the center of the aortic valve.
  • shaped distal portion 332 will be generally U-shaped, such that a distal segment 334 is disposed at an angle between 135° and 225°, and preferably at approximately 180° relative to an axial direction defined by the generally straight proximal segment 336 of shaft 322.
  • Shaped distal portion 332 will usually have a radius of curvature in the range of 20-80 mm (measured at the radial center of shaft 322), depending upon the size of the aorta in which the device is used.
  • the configuration of shaped distal portion 332 allows distal segment 334 to be positioned centrally within the lumen of the ascending aorta and distal end 324 to be axially aligned with the center of the aortic valve, thereby facilitating infusion or aspiration of fluids as well as introduction of surgical tools through opening 331 without interference with the wall of the aorta, as described more fully below.
  • shaped distal portion 332 is preshaped so as to maintain a permanent, generally U-shaped configuration in an unstressed condition.
  • a preshaped configuration may be formed by positioning a mandrel having the desired shape in first inner lumen 329, then baking or otherwise heating shaft 322 and the mandrel for a sufficient time and sufficient temperature to create a permanent set therein, e.g., 1-3 hours at a temperature in a range of 120°C to 180°C, depending upon the material used for shaft 322.
  • the U-shaped distal portion 332 may be preshaped in a more angular fashion, with bends of relatively small curvature separating segments which are either straight or of larger curvature.
  • the bends and/or segments may further be configured to engage the inner wall of the aortic arch to deflect distal end into a desired position in the ascending aorta.
  • shaped distal portion may be configured in a general "S" shape for introduction into the ascending aorta from a location superior to the aortic arch.
  • distal segment may be positioned within the ascending aorta, with proximal segment extending from the aortic arch through the brachiocephalic artery to the carotid or brachial artery, or through a penetration in the aorta itself, to a point outside of the thoracic cavity.
  • distal segment 334 may be skewed (non-coplanar) relative to a central longitudinal axis of proximal segment 336, in order to further conform to the shape of the patient's aortic arch and align with the center of the aortic valve.
  • distal segment 334 is disposed at an angle a relative to a plane containing the central axis of proximal portion 336, wherein a is between 2° and 30°, usually between 10° and 20°, and preferably about 15°.
  • the shape and dimensions of shaped distal portion 332 and angle a of distal segment 334 may vary, however, according to the configuration of the aortic arch in any individual patient.
  • the device will include a soft tip 338 attached to distal end 324 to reduce the risk of damaging cardiac tissue, particularly the leaflets of the aortic valve, in the event the device contacts such tissue.
  • Soft tip 338 may be straight or tapered in the distal direction, with an axial passage aligned with opening 331 at the distal end of shaft 322.
  • soft tip 338 will be a low durometer polymer such as polyurethane or Pebax, with a durometer in the range of 65 Shore A to 35 Shore D.
  • Radiopaque stripe or marker 339 is preferably provided on shaft 322 near distal end 324 to facilitate fluoroscopic visualization for positioning balloon 330 in the ascending aorta.
  • Radiopaque marker 339 may comprise a band of platinum or other radiopaque material.
  • a filler of barium or bismuth salt may be added to the polymer used for shaft 322 or soft tip 338 to provide radiopacity.
  • a straightening element 340 is disposed in first inner lumen 329 of shaft 322 so as to slide longitudinally relative to the shaft.
  • Straightening element 340 may comprise a tubular stylet with a longitudinal passage 344 for receiving a guidewire 342 , as described below.
  • element 340 may comprise a relatively stiff portion of the guidewire itself.
  • Straightening element 340 may be a polymeric material or a biocompatible metal such as stainless steel or nickel titanium alloy with a bending stiffness greater than that of shaft 322.
  • straightening element 340 may be advanced distally into preshaped distal portion 332 so as to straighten shaft 322, facilitating subcutaneous introduction of partitioning device 320 into an artery and advancement to the aortic arch. Straightening element 340 may then be retracted proximally relative to the shaft so that distal end 324 can be positioned in the ascending aorta with preshaped distal portion 332 conforming to the shape of the aortic arch.
  • a movable guidewire 342 is slidably disposed through first inner lumen 329, either through longitudinal passage 344 in straightening element 340, external and parallel to straightening element 340, or through a separate lumen in shaft 322.
  • Guidewire 342 extends through opening 331 in distal end 324 of shaft 322 and may be advanced into an artery distal to shaft 322, facilitating advancement of shaft 322 through the artery to the ascending aorta by sliding the shaft over the guidewire.
  • guidewire 342 is relatively stiff so as to at least partially straighten shaft 322, so that straightening element 340 is unnecessary for introduction of shaft 322.
  • guidewire 342 may be, for example, stainless steel or a nickel titanium alloy with a diameter of about 1.0 mm to 1.6 mm.
  • Shaft 322 may have any of a variety of configurations depending upon the particular procedure to be performed.
  • shaft 322 has a multi-lumen configuration with three non-coaxial parallel lumens in a single extrusion, as illustrated in Fig. 2C.
  • the three lumens include first inner lumen 329, which receives straightening element 340 and guidewire 342 and includes opening 331 at its distal end, an inflation lumen 346 which opens at an inflation orifice 347 near the distal end of shaft 322 in communication with the interior of balloon 330, and a third lumen 348 which has an opening (not shown) at distal end 324 of the shaft to sense pressure in the ascending aorta upstream of balloon 330.
  • first inner lumen 329 is preferably about 1 mm-4 mm.
  • distal opening in third lumen 348 is radially offset from opening 331 in first inner lumen 329, so that infusion or aspiration of fluid through first inner lumen 329 will not affect pressure measurements taken through third lumen 348.
  • partitioning device 320 is to be utilized for antegrade delivery of cardioplegic fluid through first inner lumen 329, it will be configured to provide a sufficient flowrate of such fluid to maintain paralysis of the heart, while avoiding undue hemolysis in the blood component (if any) of the fluid.
  • cold blood cardioplegia is the preferred technique for arresting the heart, wherein a cooled mixture of blood and a crystalloid KCl/saline solution is introduced into the coronary arteries to perfuse and paralyze the myocardium.
  • the cardioplegic fluid mixture is preferably run through tubing immersed in an ice bath so as to cool the fluid to a temperature of about 3°C - 10°C prior to delivery through inner lumen 329.
  • the cardioplegic fluid is delivered through inner lumen 329 at a sufficient flowrate and pressure to maintain a pressure in the aortic root (as measured through third lumen 348) high enough to induce flow through the coronary arteries to perfuse the myocardium.
  • first inner lumen 329 is configured to facilitate delivery of the cardioplegic fluid at a rate of about 250-350 ml/min.
  • inner lumen 329 usually has a cross-sectional area of at least about 4.5 mm 2 , and preferably about 5.6-5.9 mm 2 .
  • D-shaped lumen 329 in Fig. 2C has a straight wall about 3.3 mm in width, and a round wall with a radius of about 1.65 mm.
  • a completely circular lumen 329 (not pictured), could have an inner diameter of about 2.7 mm.
  • Inner lumen 329 could be significantly smaller, however, if the cardioplegic fluid did not have a blood component so that it could be delivered under higher pressures without risk of hemolysis. Because of its myocardial protective aspects, however, the aforementioned blood/KCl mixture is presently preferred, requiring a somewhat larger lumen size than would be required for a crystalloid KCl cardioplegic fluid without blood.
  • Shaft 322 may be constructed of any of a variety of materials, including biocompatible polymers such as polyurethane, polyvinyl chloride, polyether block amide, or polyethylene. In a preferred embodiment of the device shown in Fig. 2A, shaft 322 is urethane with a shore durometer in the range of 50D-100D. Shaft 322 may have a bending modulus in the range of 70 to 100 kpsi, preferably about 80-90 kpsi. A bending modulus in this range provides sufficient stiffness to optimize pushability from a femoral or iliac artery to the ascending aorta, while providing sufficient flexibility to navigate the tortuous iliac artery and the aortic arch.
  • biocompatible polymers such as polyurethane, polyvinyl chloride, polyether block amide, or polyethylene.
  • shaft 322 is urethane with a shore durometer in the range of 50D-100D.
  • Shaft 322 may have a bending modulus in
  • this bending modulus also facilitates exertion of a distally-directed force on shaft 322 from proximal end 326 to maintain the position of balloon 330 against the outflow of blood from the left ventricle as the balloon is inflated.
  • the dimensions, geometry and/or materials of shaft 322, as well as coil 360 may be varied over the length of the shaft so that the shaft exhibits variable bending stiffness in various regions.
  • preshaped distal portion 332 may be more flexible for tracking through the aortic arch, whereas proximal portion 336 may be stiffer for pushability and resistance to displacement.
  • Balloon 330 may be constructed of various materials and in various geometries.
  • balloon 330 has a collapsed profile small enough for introduction into the femoral or iliac artery, e.g. 4-9 mm outside diameter, and an expanded (inflated) profile large enough to completely occlude the ascending aorta, e.g. 20-40 mm outside diameter.
  • the ratio of expanded profile diameter to collapsed profile diameter will thus be between 2 and 10, and preferably between 5 and 10.
  • the balloon is further configured to maximize contact of the working surface of the balloon with the aortic wall to resist displacement and to minimize leakage around the balloon, preferably having a working surface with an axial length in the range of about 3 cm to about 7 cm when the balloon is expanded. Textural features such as ribs, ridges or bumps may also be provided on the balloon working surface for increased frictional effects to further resist displacement.
  • Balloon 330 preferably has some degree of radial expansion or elongation so that a single balloon size may be used for aortas of various diameters.
  • Materials which may be used for balloon 330 include polyurethanes, polyethylene terephthalate (PET), polyvinyl chloride (PVC), polyolefin, latex, ethylene vinyl acetate (EVA) and the like.
  • PET polyethylene terephthalate
  • PVC polyvinyl chloride
  • EVA ethylene vinyl acetate
  • balloon 330 must have sufficient structural integrity when inflated to maintain its general shape and position relative to shaft 322 under the systolic pressure of blood flow through the ascending aorta.
  • balloon 330 is constructed of polyurethane or a blend of polyurethane and polyvinyl such as PVC.
  • balloon may be further provided with a plurality of folds or pleats which allow the balloon to be collapsed by evacuation to a small collapsed profile for introduction into a femoral or iliac artery.
  • Fig. 2D illustrates the deflated and inflated profile of one preferred embodiment of the elastomeric balloon 330 of the endoaortic partitioning catheter 320.
  • the deflated profile 330' has an oblong or football shape which is imparted by the balloon molding process.
  • the wall thickness of the molded balloon 330' in its deflated state is typically about 0.090-0.130 mm.
  • the deflated balloon 330' has a diameter of approximately 12 mm.
  • the inflated balloon 330 assumes a roughly spherical shape with a maximum diameter of approximately 40 mm when inflated.
  • the football shape of the molded balloon has been shown to be advantageous in that the deflated balloon 330' has a deflated profile which is less bulky and smoother than for other balloon geometries tested. This allows the deflated balloon 330' to be folded and more easily inserted through a percutaneous puncture into the femoral artery or through an introducer sheath or a dual arterial cannula/introducer sheath.
  • Other acceptable geometries for the molded elastomeric balloon 330 include a simple cylinder, an enlarged cylinder with tapered ends or a spherical shape.
  • Fig. 2E illustrates another preferred embodiment of the elastomeric balloon 330 of the endoaortic partitioning catheter 320.
  • the distal end 200 of the deflated balloon 300' is inverted and adhesively attached to the distal end 202 of the catheter shaft 322.
  • the balloon is inflated to its inflated profile 330, the distal end 202 of the catheter shaft 322 is protected by the inflated balloon 330 and prevented from touching the aortic valve or the aortic walls, obviating the need for the soft tip 338 of the embodiment of Figs. 2A, 2B and 2D.
  • a triple-arm adapter 364 is attached to the proximal end 326 of shaft 322.
  • Triple-arm adapter 364 includes a working port 366 in communication with first inner lumen 329 through which straightening element 340 and guidewire 342, may be introduced, to straighten the shaft 322 to facilitate introduction of the catheter 320 into the femoral artery.
  • straightening element 340 and guidewire 342 may be withdrawn to allow introduction of an endovascular device through the working port 366 into the first inner lumen 329 of the catheter.
  • Working port 366 may also be adapted for infusion of fluid such as cardioplegic fluid, saline or contrast solution, as well as for aspiration of blood, fluids and debris through first inner lumen 329.
  • Triple-arm adapter 364 further includes an inflation port 368 in communication with the inflation lumen and configured for connection to an inflation fluid delivery device such as a syringe 370 or other commercially available balloon-inflation device such as the IndeflatorTM available from Advanced Cardiovascular Systems, Inc. of Santa Clara, CA.
  • a pressure measurement port 372 is in communication with the third lumen (348 or 354) and is adapted for connection to a pressure measurement device.
  • shaft 322 includes only first inner lumen 329 and inflation lumen 358 as in Figures 26B, 28 and 30, port 372 may be in communication with first inner lumen 329 and configured for pressure measurement, fluid infusion or aspiration.
  • FIG. 3A-3B A second alternative embodiment of partitioning device 320 is illustrated in Figs. 3A-3B.
  • shaft 322 is positionable in an interior lumen 420 of a guiding catheter 422.
  • Device 320 may be configured as described above in reference to Fig. 2A, including balloon 330 near distal end 324, inner lumen 329, inflation lumen 346, pressure lumen 348, soft tip 338 attached to distal end 324, and triple-arm adapter 364 attached to proximal end 326.
  • Guiding catheter 422 has a proximal end 424 and a distal end 426, with axial lumen 420 extending therebetween.
  • a soft tip (not shown) may be attached to distal end 426 to minimize injury to the aorta or aortic valve in the event of contact therewith.
  • a proximal adapter 428 is attached to proximal end 424, and has a first port 430 in communication with lumen 420 through which shaft 322 may be introduced, and a second port 432 in communication with lumen 420 for infusing or aspirating fluid.
  • Port 430 may further include a hemostasis valve.
  • Guiding catheter 422 also has a distal portion 434 which is either preshaped or deflectable into a shape generally conforming to the shape of the aortic arch.
  • guiding catheter 422 is preshaped in a generally U-shaped configuration, with a radius of curvature in the range of 20-80 mm.
  • a stylet (not shown) like that described above in connection with Figures 25-30 is provided for straightening distal portion 434 for purposes of percutaneously introducing guiding catheter 422 into an artery.
  • guiding catheter 422 is introduced into an artery, e.g. a femoral or iliac artery, and advanced toward the heart until distal end 426 is in the ascending aorta.
  • a guidewire (not shown) may be used to enhance tracking.
  • shaft 322 may be introduced through port 430 and lumen 420 and advanced toward the heart until balloon 330 is disposed between the coronary ostia and the brachiocephalic artery, distal to the distal end 426 of guiding catheter 422.
  • the distal portion 332 of shaft 322 is shaped to conform to the aortic arch by preshaped portion 434 of guiding catheter 422. Balloon 330 is then inflated to fully occlude the ascending aorta and block blood flow therethrough.
  • partitioning device 320 includes a shaping element 440 positionable in a lumen in shaft 322, such as third inner lumen 348.
  • Shaping element 440 has a proximal end 442, a distal end 444 and a preshaped distal portion 446.
  • Preshaped distal portion 446 may be generally U-shaped as illustrated, or may have an angular, "S"-shaped or other configuration in an unstressed condition, which will shape distal portion 332 to generally conform to at least a portion of the patient's aortic arch.
  • Shaping element 440 is preferably stainless steel, nickel titanium alloy, or other biocompatible material with a bending stiffness greater than that of shaft 322 so as to deflect distal portion 332 into the desired shape.
  • Shaping element 440 may be a guidewire over which shaft 322 is advanced to the ascending aorta, or a stylet which is inserted into third inner lumen 348 after shaft 322 is positioned with balloon 330 in the ascending aorta.
  • shaping element 440 is configured to position distal end 324 of shaft 322 in a radial position within the ascending aorta to be spaced apart from the interior wall thereof, and in particular, axially aligned with the center of the aortic valve.
  • partitioning device 320 is coupled to an arterial bypass cannula 450 so as to allow both device 320 and cannula 450 to be introduced through the same arterial puncture.
  • Arterial bypass cannula 450 is configured for connection to a cardiopulmonary bypass system for delivering oxygenated blood to the patient's arterial system.
  • Arterial bypass cannula 450 has a distal end 452, a proximal end 454, a blood flow lumen 456 extending between proximal end 454 and distal end 452, and an outflow port 458 at distal end 452.
  • a plurality of additional outflow ports 460 may be provided along the length of arterial bypass cannula 450, particularly near distal end 452.
  • arterial bypass cannula 450 has a length between about 10 cm and 60 cm, and preferably between about 15 cm and 30 cm.
  • An adaptor 462 is connected to proximal end 454 of bypass cannula 450, and includes a first access port 464 and a second access port 466, both in fluid communication with blood flow lumen 456.
  • Access port 466 is configured for fluid connection to tubing from a cardiopulmonary bypass system, and preferably has a barbed fitting 468.
  • Access port 464 is configured to receive partitioning device 320 therethrough.
  • a hemostasis valve 470 shown in Figs. 5C and 5E, is mounted in access port 464 to prevent leakage of blood and other fluids through access port 464 whether or not shaft 322 of partitioning device 320 is positioned therein.
  • Hemostasis valve 470 may have any number of well-known constructions, including, for example, an elastomeric disk 469 having one or more slits 472 through which shaft 422 may be positioned, and a diaphragm 471 adjacent to the disk with a central hole 474 for sealing around the periphery of shaft 322.
  • a hemostasis valve of this type is described in U.S. Patent No. 4,000,739.
  • Other types of hemostasis valves may also be used, such as duck-bill valves, O-ring seals, and rotational or sliding mechanical valves.
  • a Touhy-Borst valve 473 including a threaded, rotatable cap 475 may be provided on the proximal end of access port 464 to facilitate clamping and sealing around shaft 322 by tightening cap 475, which compresses O-rings 477 about shaft 322.
  • Shaft 322 of partitioning device 320 and blood flow lumen 456 of bypass cannula 450 are configured and dimensioned to facilitate sufficient blood flow through blood flow lumen 456 to support full cardiopulmonary bypass with complete cessation of cardiac activity, without an undesirable level of hemolysis.
  • arterial bypass cannula 450 has an outer diameter of 6 mm to 10 mm
  • blood flow lumen 456 has an inner diameter of 5 mm to 9 mm.
  • Shaft 322 of partitioning device 320 has an outer diameter in the range of 2 mm to 5 mm. In this way, blood flow lumen 456, with shaft 322 positioned therein, facilitates a blood flow rate of at least about 4 liters/minute at a pump pressure of less than about 33.3 kPa (250 mmHg).
  • Arterial bypass cannula 450 is preferably introduced into an artery, usually a femoral artery, with partitioning device 320 removed from blood flow lumen 456.
  • An obturator 476 illustrated in Fig. 5D, may be positioned in blood flow lumen 456 such that the tapered distal end 478 of obturator 476 extends distally from the distal end 452 of arterial bypass cannula 450.
  • the arterial bypass cannula 450 may be introduced into the artery by various techniques including percutaneous methods such as the Seldinger technique, but is usually of sufficient size to require a surgical cutdown.
  • a guidewire 480 may be slidably positioned through a lumen 482 in obturator 476 to facilitate introduction of arterial bypass cannula 450.
  • Guidewire 480 is advanced into the artery through an arteriotomy, and arterial bypass cannula 450 with obturator 476 positioned therein is advanced into the artery over guidewire 480.
  • Obturator 476 may then be removed, allowing partitioning device 320 to be introduced into the artery through blood flow lumen 456, usually over guidewire 480.
  • Guidewire 480 may be advanced toward the heart and into the ascending aorta to facilitate positioning the distal end 324 of partitioning device 320 therein.
  • the shaft 322 of partitioning device 320 has an outer diameter of approximately 3.45 mm or 10.5 French (Charrière scale).
  • the three lumen shaft 320 is extruded from a thermoplastic elastomer with a Shore D durometer of approximately 72.
  • the D-shaped infusion lumen 329 has a height from the interlumen wall 702 to the exterior wall 700 of approximately 2.08 mm which allows sufficient flow rate for delivery of cardioplegic fluid and provides sufficient diametrical clearance for passage of an endovascular device through the infusion lumen 329 for performing an endovascular procedure within the heart or blood vessels of the patient.
  • the balloon inflation lumen 346 in this embodiment has a width of approximately 1.40 mm, and the pressure monitoring lumen 348 has a width of approximately 0.79 mm.
  • the interlumen wall 702 between the three lumens and the exterior wall 700 of the shaft 322 have a wall thickness of approximately 0.20 mm.
  • the blood flow lumen 456 allows a blood flow rate of approximately 6 liters/minute at a pump pressure of about 46.7 kPa 350 mmHg.
  • the choice of what size arterial bypass cannula 450 to use for a given patient will depend on the size of the patient's femoral arteries and overall body size which determines the flow rate required.
  • arterial bypass cannula 450 may be configured so that partitioning device 320 is not removable from blood flow lumen 456.
  • bypass cannula 450 is introduced into an artery with partitioning device 320 positioned in blood flow lumen 456.
  • Partitioning device 320 may be slidable within a limited range of movement within blood flow lumen 456.
  • partitioning device 320 may be fixed to arterial bypass cannula 450 to prevent relative movement between the two.
  • shaft 322 may be extruded from the same tubing which is used to form arterial bypass cannula 450.
  • shaft 322 may be attached within the interior of blood flow lumen 456 or at the distal end 452 of arterial bypass cannula 450.
  • distal end 452 of bypass cannula 450 may be tapered to seal around shaft 322 and may or may not be bonded to shaft 322.
  • side ports 460 permit outflow of blood from blood flow lumen 456.
  • Fig. 6 shows a schematic representation of a patient's heart 210 partly cut-away to show some of the internal structures of the heart.
  • the endoaortic partitioning device 212 has been percutaneously introduced into an artery, such as the femoral artery, by the Seldinger technique or an arterial cutdown and advanced into the ascending aorta 223.
  • the occlusion balloon 227 is inflated within the ascending aorta 223 to occlude the aortic lumen and to separate the heart 210 and the aortic root 226 from the remainder of the circulatory system.
  • the circulatory system is placed on cardiopulmonary bypass and the heart is stopped, as by infusion of a cardioplegic agent or by hypothermic arrest or other means, simultaneous with the inflation of the occlusion balloon 227.
  • One or more endovascular devices are introduced through an internal lumen in the endoaortic partitioning device 212 to perform a diagnostic or therapeutic endovascular procedure within the heart or blood vessels of the patient.
  • a fiberoptic cardioscope or angioscope 237 has been introduced through the endoaortic partitioning device 212 into the aortic root 226 for visualizing the internal structures of the heart 210 and the blood vessels.
  • the aortic root 226 and/or the chambers of the heart 210 and its blood vessels can be filled with a transparent liquid, for example saline solution or crystaloid cardioplegic solution, infused through a lumen the endoaortic partitioning device 212 to displace the blood and provide a clear view of structures such as the aortic or mitral valve, the aortic root or the coronary arteries.
  • the angioscope 237 can be used for diagnosis of insufficient, stenotic or calcified heart valves, atrial or ventricular septal defects, patent ductus arteriosus, coronary artery disease or other conditions. This endovascular prodedure may be performed in preparation for or for observation during a therapeutic procedure such as repair or replacement of a heart valve or as an adjunct to a concomitant procedure on the heart.
  • Fig. 6 shows a left ventricular venting catheter 238 introduced into left ventricle of the heart 210 to vent blood and other fluids from the heart to relieve pressure that could cause distention of the heart while the patient is on cardiopulmonary bypass.
  • Figs. 1 and 7 show another embodiment of the system for performing endovascular procedures of the present invention.
  • the endoaortic partitioning device 10 has previously been introduced into the ascending aorta 12 and the occlusion balloon 11 inflated to occlude the aortic lumen, as described above.
  • a valvuloplasty catheter 500 has been introduced through an internal lumen 40 of the endoaortic partitioning device 10, as shown in Fig. 1.
  • the valvuloplasty catheter 500 has an expandable dilatation balloon 502 on the distal end of an elongated shaft 504.
  • a fluid-filled syringe 508 or other inflation device is attached to a fitting 506 on the proximal end of the shaft 504.
  • An inflation lumen within the shaft 504 connects the fitting 506 with the interior of the dilatation balloon 502.
  • the dilatation balloon 502 is introduced through the lumen 40 of the endoaortic partitioning device 10 in a deflated condition until the dilatation balloon 502 emerges from the distal end 41 of the endoaortic partitioning device 10 into the aortic root.
  • the dilatation balloon 502 is advanced across the patient's aortic valve 66 and the dilatation balloon 502 is expanded within the aortic valve 66, as shown in Fig. 7, to relieve a stenosis of the valve or to mobilize calcified valve leaflets.
  • the dilatation balloon 502 is then deflated and the valvuloplasty catheter 500 is withdrawn from the patient.
  • Fig. 8 shows an exemplary embodiment of the system of the present invention that combines an electrophysiology mapping and ablation catheter 660 with the endoaortic partitioning device previously described.
  • Fig. 8 shows a schematic representation of the left side of a patient's heart cut away to show the interior of the left ventricle 13 and left atrium 14.
  • the endoaortic partitioning device 10 has been percutaneously introduced into the ascending aorta 12 and the occlusion balloon 11 may be inflated to occlude the aortic lumen and to separate the heart and the aortic root from the remainder of the circulatory system.
  • a multi-electrode endocardial electrophysiology mapping and ablation catheter 660 is introduced through an internal lumen 40 of the endoaortic partitioning device 10.
  • the electrophysiology catheter 660 has been advanced through the aortic valve 66 and into the left ventricle 13 of the heart.
  • the electrophysiology catheter 660 has four wire assemblies 662 that extend through an elongated catheter shaft 666.
  • Each of the wire assemblies 662 has multiple electrodes 664, six per wire assembly in this illustrative example, which are each connected to separate insulated electrical wires (not shown) within the catheter shaft 666. Separate electrical connectors (not shown) are connected to each of the electrical wires on the proximal end of the catheter 660.
  • the wire assemblies 662 are compressible so that they can be withdrawn into an internal lumen 668 within the catheter shaft 666 for introduction of the device 660 through the endoaortic partitioning device 10.
  • the wire assemblies 662 When extended from the catheter shaft 666, the wire assemblies 662 expand within the left ventricle 13 of the heart to hold the electrodes 664 in electrical contact with the interior wall of the ventricle 13.
  • the electrophysiology catheter 660 can likewise be advanced through the mitral valve 520 and expanded in the left atrium 14 of the heart.
  • the electrophysiology catheter 660 can be used to map the electrically conductive pathways in the ventricular wall and to locate any abnormal foci that could result in atrial or ventricular tachycardia or other electrophysiological problems of the heart. Once the abnormal foci have been localized they can be ablated by applying a direct or alternating current across the two closest adjoining electrodes to the site sufficient to permanently disrupt the flow of electrical impulses along that path. Alternatively, another ablation catheter may be used to localize and ablate the abnormal foci once they have been diagnosed. Specific examples of electrophysiology mapping and ablation catheters suitable for use with the system for performing endovascular procedures of the present invention are described in the following patents; U.S. patent 4,699,147 granted to Donald A. Chilson and Kevin W.
  • the system for performing endovascular procedures of the present invention can be operated in a variety of different operating modes depending on the nature and circumstances of the endovascular procedure to be performed.
  • either or both of the endovascular procedure and the surgical procedure may be performed while the patient's circulatory system is supported by a cardiopulmonary bypass system.
  • the endoaortic occlusion balloon of the endoaortic partitioning catheter may be inflated to isolate the patient's heart and a cardioplegic agent infused through the endoaortic partitioning catheter to stop the patient's heart while performing the endovascular procedure and/or the surgical procedure.
  • a cardioplegic agent infused through the endoaortic partitioning catheter to stop the patient's heart while performing the endovascular procedure and/or the surgical procedure.
  • the endovascular procedure and the surgical procedure may be performed simultaneously or serially in either order.
  • This operating mode discussed above is the combination of angioplasty, atherectomy or endarterectomy with CABG surgery in order to realize a more complete revascularization of the patient's heart.
  • one or more endovascular procedures may be performed on the patient's heart without combining them with another surgical procedure.
  • This mode of operation will be advantageous when it is desirable to stop the heart to facilitate performing the endovascular procedure or to relieve the stress on the heart during a high risk interventional procedure. This may allow the application of various endovascular procedures to patients whose cardiac function is highly compromised and therefore might not otherwise be good candidates for the procedure.
  • the endoaortic partitioning catheter can be used as a guiding catheter for introducing an endovascular device and for performing an endovascular procedure while the patient is on partial cardiopulmonary support without inflating the occlusion balloon or inducing cardiac arrest.
  • the endoaortic partitioning catheter can be activated to occlude the aorta and induce cardioplegia, thereby converting the patient from partial cardiopulmonary support to full cardiopulmonary bypass.
  • This mode of operation would be advantageous when it was desired to follow the endovascular procedure with another surgical procedure on the heart using either a thoracoscopic or standard open chest approach. It would also be advantageous when performing a high risk interventional procedure so that, in the event of complications, the patient can be immediately placed on full cardiopulmonary bypass and prepared for emergency surgery without delay.
  • the system for performing endovascular procedures built in accordance with the present invention provides a number of advantages heretofore unknown. Particularly, it allows a compatible combination of devices for performing endovascular procedures with the capability of performing complete cardioplumonary bypass and cardioplegic arrest for myocardial preservation. It also allows the combination of one or more endovascular procedures with surgical procedures on the heart or blood vessels in a manner that facilitates both types of procedures and reduces the invasiveness of the procedures, thereby reducing the trauma and morbidity to the patient as a result.

Abstract

This invention is a system for inducing cardio-plegia arrest and performing an endovascular procedure within the heart or blood vessels of a patient. An endo-aortic partitioning catheter (10) has an inflatable balloon (11) which occludes the ascending aorta (12) when inflated. Cardio-plegia fluid may be infused through a lumen of the endo-aortic partitioning catheter (39) to stop the heart while the patient's circulatory system is supported on cardiopulmonary bypass. One or more endovascular devices (500) are introduced through an internal lumen (40) of the endo-aortic partitioning catheter (30) to perform a diagnostic or therapeutic endovascular procedure within the heart or blood vessels of the patient. Surgical procedures such as coronary artery bypass surgery or heart valve replacement may be performed in conjunction with the endovascular procedure while the heart is stopped. Embodiments of the system are described for performing, e.g., fiberoptic angioscopy of structures within the heart and its blood vessels, and valvuloplasty for correction of valvular stenosis.

Description

    FIELD OF THE INVENTION
  • The present invention relates generally to devices for performing diagnostic or therapeutic endovascular procedures within the circulatory system of a patient. More particularly, it relates to a system for isolating the heart and coronary blood vessels of a patient from the remainder of the arterial system, for inducing cardioplegic arrest in the heart and for performing diagnostic or therapeutic endovascular procedures within the heart or blood vessels of the patient while the heart is stopped. A system according to the preamble of claim 1 is known from EP-A-0 604 803.
  • BACKGROUND OF THE INVENTION
  • Recent trends in the advancement of surgical technology have tended toward less and less invasive procedures in order to reduce morbidity and mortality of the surgical procedures, thereby increasing the benefit to the patient. An important advancement in the area of cardiac surgery is represented by co-owned, US patent numbers 5 735 290 and 5 814 097, which describe, in detail, endoaortic catheter devices and systems for inducing cardioplegic arrest in the heart of a patient and for carrying out surgical procedures, such as coronary artery bypass graft (CABG) surgery or heart valve replacement surgery, on the arrested heart. One surgical approach presented in the parent applications is known as closed-chest or port-access cardiac surgery, in which access is gained to the exterior of the heart through percutaneous intercostal penetrations in the wall of the patient's chest. In port-access cardiac surgery the surgical procedure is carried out using instruments that operate through the intercostal penetrations while the heart is stopped using the endoaortic catheter. Another surgical approach presented in the parent applications is an endovascular approach, in which diagnostic or therapeutic endovascular devices are inserted through a lumen in the endoaortic catheter to carry out an endovascular procedure within the heart or blood vessels of the patient. The present invention addresses the endovascular surgical approach and the endovascular procedures that can be carried out using the endoaortic catheter.
  • It has been suggested previously to combine certain endovascular procedures as an adjunct to cardiac surgery procedures, such as combining intraoperative coronary balloon angioplasty with conventional coronary artery bypass grafting in order to achieve more complete revascularization of the patient's coronary arteries. To date there has only been very limited clinical acceptance of this combined procedure. One reason for this limited acceptance may be that the standard aortic crossclamps used for isolating the heart from the remainder of the arterial system during CABG surgery occlude the aortic lumen, preventing the angioplasty catheter from being introduced into the coronary arteries by the usual transluminal approach.
  • WO95/08364 discloses an endovascular device for partitioning the ascending aorta and a system for arresting the heart to facilitate the performance of procedures such as heart valve replacement. The possibility of introducing a valve cutter into the heart, through an internal lumen of the endovascular device, is mentioned.
  • The present invention provides a system according to claim 1. The invention may thus allow the combination of diagnostic and therapeutic endovascular procedures with cariopulmonary bypass and carioplegic arrest in a manner that facilitates rather than inhibits the performance of both procedures. That is to say that the isolation of the heart and its blood vessels necessary for cardioplegia and cardiopulmonary support can be accomplished entirely through endovascular means without the necessity of a gross thoracotomy, and that, simultaneously, a path is created for introduction for one or more devices for performing a diagnostic or therapeutic endovascular procedure.
  • Endovascular procedures which lend themselves to this approach include diagnostic procedures, such as electrophysiological mapping of the heart or ablation of electrophysiological structures within the heart.
  • In keeping with the foregoing discussion, the present invention may take the form of a system that includes an endoaortic catheter for inducing cardioplegic arrest in the heart of a patient and at least one endovascular device which is slidably received within a lumen of the endoaortic catheter for performing an endovascular procedure on the patient's heart. A cardiopulmonary bypass (CPB) system, such as a femoral-femoral CPB system, may be used in conjunction with the endoaortic catheter for supporting the systemic circulation of the patient while the heart is stopped. The endovascular procedure can be performed as the sole procedure on the patient or it can be performed in conjunction with another cardiac surgical procedure, such as a port-access CABG procedure or heart valve replacement procedure, as described in the parent cases. The endovascular procedure can be carried out on the patient's heart while it is stopped or it can be performed on the beating heart in order to reduce the time that the heart is stopped (often referred to as the crossclamp time.)
  • The endoaortic partitioning catheter which is the foundation of the system for performing endovascular procedures is introduced percutaneously or by direct cut-down through the femoral artery. This catheter must carry adjacent its tip an inflatable cuff or balloon of sufficient size that upon being inflated it is able to completely occlude the ascending aorta. The length of the balloon should preferably not be so long as to impede the flow of blood or other solution to the coronary arteries or to the brachiocephalic, left carotid or left subclavian arteries. A balloon length of about 40 mm and diameter of about 35 mm is suitable in humans. The balloon may be of a cylindrical, spherical, football-shaped or other appropriate shape to fully and evenly accommodate the lumen of the ascending aorta. This maximizes the surface area contact with the aorta, and allows for even distribution of occlusive pressure.
  • The balloon of the catheter is in fluid communication with an inflation lumen that extends the length of the catheter. The balloon is preferably inflated with a saline solution to avoid the possibility of introducing into the patient an air embolism in the event that the balloon ruptured. The balloon should be inflated to a pressure sufficient to prevent regurgitation of blood into the aortic root and to prevent migration of the balloon into the root whilst not being so high as to cause damage or dilation to the aortic wall. An intermediate pressure of the order of 350 mmHg, for example, has been proven effective.
  • The endoaortic partitioning catheter is preferably introduced under fluoroscopic guidance over a suitable guidewire. Transoesophageal echocardiography can alternatively be used for positioning the aortic catheter. The catheter may serve a number of separate functions and the number of lumina in the catheter will depend upon how many of those functions the catheter is to serve. The catheter can be used to introduce the cardioplegic agent, normally in solution, into the aortic root via a perfusion lumen. The luminal diameter will preferably be such that a flow of the order of 250-500 ml/min of cardioplegic solution can be introduced into the aortic root under positive pressure to perfuse adequately the heart by way of the coronary arteries. The same lumen can, by applying negative pressure to the lumen from an outside source, effectively vent the left heart of blood or other solutions.
  • In addition, the endoaortic partitioning catheter is adapted for introduction of one or more endovascular devices through an internal lumen of the catheter. This may be a separate lumen from the inflation lumen and the perfusion lumen discussed above or, for simplicity of construction and to maximize the potential lumen diameter, the perfusion lumen may be combined with the lumen for introduction of endovascular devices. It is preferable that the diameter and cross-sectional design of the internal lumina are such that the external diameter of the catheter in its entirety is small enough to allow its introduction into the adult femoral artery by either percutaneous puncture or direct cut-down.
  • In a first aspect of the invention, the system for performing endovascular procedures combines the endoaortic partitioning catheter with an electrophysiology mapping and ablation catheter for diagnosing and treating electrophysiological conditions of the heart.
  • A number of important advantages accrue from the combination of the endoaortic partitioning catheter with these endovascular diagnostic and therapeutic devices. Introducing endovascular devices through a lumen of the endoaortic partitioning catheter allows the patient's heart to be stopped and the circulatory system supported on cardiopulmonary bypass while performing the endovascular procedure. This may allow the application of various endovascular procedures to patients whose cardiac function is highly compromised and therefore might not otherwise be good candidates for the procedure. It also allows the endovascular procedures to be performed as an adjunct to other cardiac surgical procedures. With the devices of the prior art, it would be difficult to perform many of these endovascular procedures as an adjunct to cardiac surgery because the standard aortic crossclamps used entirely occlude the lumen of the aorta preventing the endovascular devices from being introduced through the normal transluminal route. Many of the diagnostic or therapeutic endovascular procedures will also benefit from performing the procedures while the heart is still and with no blood flow through the heart that would complicate the procedures. For instance ablation of anomalous structures such as calcification or scarring of the heart valves or laser ablation of abnormal electrophysiological foci can be more precisely and accurately controlled.
  • In an alternate mode of operation the endoaortic partitioning catheter can be used as a guiding catheter for introducing an endovascular device and for performing an endovascular procedure while the patient is on partial cardiopulmonary support without inflating the occlusion balloon or inducing cardiac arrest. If and when it is desired, the endoaortic partitioning catheter can be activated to occlude the aorta and induce cardioplegia, thereby converting the patient from partial cardiopulmonary support to full cardiopulmonary bypass. This mode of operation would be advantageous when it was desired to follow the endovascular procedure with another surgical procedure on the heart using either a thoracoscopic or standard open chest approach. It would also be advantageous when performing a high risk interventional procedure so that, in the event of complications, the patient can be immediately placed on full cardiopulmonary bypass and prepared for emergency surgery without delay. These and other advantages of the present invention will become apparent from reading and understand the following detailed description along with the accompanying drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Fig. 1 schematically illustrates a system for performing endovascular procedures using on endovascular device outside the scope of the present invention.
  • Fig. 2A is a side elevation view of a first embodiment of an endoaortic partitioning device for partitioning the ascending aorta between the coronary ostia and brachiocephalic artery constructed in accordance with the principles of the present invention. Fig. 2B is an end view of a distal portion of the device of Fig. 2A illustrating the skew of the shaped distal portion. Fig. 2C is a transverse cross section taken along the line 2C-2C in Fig. 2A. Fig. 2D illustrates the deflated and inflated profile of one preferred embodiment of the elastomeric balloon of the endoaortic partitioning device. Fig. 2E illustrates another preferred embodiment of the elastomeric balloon of the endoaortic partitioning catheter.
  • Fig. 3A is a side elevation view of a second embodiment of an endoaortic partitioning device constructed in accordance with the principles of the present invention. Fig. 3B is a transverse cross section of the partitioning device of Fig. 3A taken along the line 3B-3B.
  • Fig. 4A is a side elevation view of a third embodiment of an endoaortic partitioning device constructed in accordance with the principles of the invention. Fig. 4B is a transverse cross section taken along the line 4B-4B in Fig. 4A, showing a shaping element positioned in an inner lumen in the shaft.
  • Figs. 5A-5D shows a fourth embodiment of the endoaortic partitioning device which is coupled to an arterial bypass cannula so as to allow both the partitioning device and the cannula to be introduced through a single arterial puncture.
  • Fig. 6 is a schematic partly cut-away representation of a patient's heart with the endoaortic partitioning device percutaneously placed within the ascending aorta and with an angioscope and a left ventricular venting catheter introduced into the aortic root and left ventricle respectively, via separate lumina within the aortic partitioning device.
  • Fig. 7 is a view of a patient's heart with the endoaortic partitioning device placed in the ascending aorta and with a valvuloplasty balloon catheter inflated within the aortic valve.
  • Fig. 8 is a view of a patient's heart with the endoaortic partitioning device placed in the ascending aorta and with an electrophysiology mapping and ablation catheter within the left ventricle of the heart.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The invention provides a system for performing endovascular procedures including an endoaortic device for partitioning the ascending aorta in combination with an endovascular device for performing a diagnostic or therapeutic endovascular procedure within the heart of a patient. The system may also include a means for selectively arresting the heart, such as a means for retrograde or antegrade infusion of cardioplegic fluid for inducing cardioplegic arrest. The invention is especially useful in conjunction with minimally-invasive cardiac procedures, in that it allows the heart to be arrested and the patient to be placed on cardiopulmonary bypass using only endovascular devices, obviating the need for a thoracotomy or other large incision. The procedures with which the invention will find use include diagnostic procedures, such as electrophysiological mapping of the heart, and therapeutic procedures, such as, ablation of electrophysiological structures within the heart. The endovascular procedure which is performed using the system of the invention may be the primary procedure performed on the patient, or, alternatively, the endovascular procedure may be performed as an adjunct to another endovascular, thoracoscopic or open heart procedure.
  • Reference is made to Fig. 1 which schematically illustrates the overall system for performing endovascular procedures and the individual components thereof. The endovascular procedure system includes an elongated aortic occlusion or delivery catheter 10 which has an expandable member 11 on a distal portion of the catheter which, when inflated as shown, occludes the ascending aorta 12 to separate the left ventricle 13 and upstream portion of the ascending aorta from the rest of the patient's arterial system and securely positions the distal end of the catheter within the ascending aorta. An endovascular device for performing a diagnostic or therapeutic procedure, represented here by a valvuloplasty catheter 500 which is outside the scope of the invention, is slidably received within an internal lumen of the aortic occlusion catheter 10. A cardiopulmonary bypass system 18 removes venous blood from the femoral vein 16 through the blood withdrawal catheter 17 as shown, removes CO2 from the blood, oxygenates the blood, and then returns the oxygenated blood to the patient's femoral artery 15 through the return catheter 19 at sufficient pressure so as to flow throughout the patient's arterial system except for the portion blocked by the expanded occluding member 11 on the aortic occluding catheter 10. A fluid containing cardioplegic agents can be delivered through an internal lumen of the endoaortic occluding catheter in an antegrade manner into the aortic root and into the coronary arteries to paralyze the myocardium. Alternatively, a retrograde cardioplegia balloon catheter 20 may be placed within the patient's venous system with the distal end of the catheter extending into the coronary sinus 21 to deliver a fluid containing cardioplegic agents to the myocardium in a retrograde manner through the patient's coronary venous system to paralyze the entire myocardium.
  • The elongated occluding catheter 10 extends through the descending aorta to the left femoral artery 23 and out of the patient through a cut down 24. The proximal extremity 25 of the catheter 10 which extends out of the patient is provided with a multi-arm adapter 26 with one arm 27 adapted to receive an inflation device 28. The adapter 26 is also provided with a second arm 30 with main access port having a hemostasis valve 31 through which the endovascular device 500 is inserted into internal lumen of the aortic occlusion catheter 10. The function of the hemostasis valve 31 may also be provided by a separate adapter which connects to second arm 30 of the multi-arm adapter 26. A third arm 32 connected to bypass line 33 is provided to direct blood, irrigation fluid, and the like to or from the system. A suitable valve 34 is provided to open and close the bypass line 33 and direct the fluid passing through the bypass line to a discharge line 35 or a line 36 to a blood filter and recovery unit 37. A return line may be provided to return any filtered blood, which will be described hereinafter, to the cardiopulmonary bypass system 18 or other blood conservation system.
  • The details of the aortic occlusion catheter 10 and the disposition of the distal extremity thereof within the aorta are best illustrated in Fig. 7 which again shows an endovascular device outside the scope of the invention. As indicated, the catheter 10 includes an elongated catheter shaft 39 which has a first inner lumen 40 in fluid communication with the main access port 31 in the second arm of the adapter 26 and is adapted to facilitate the passage of an endovascular device, again represented by a valvuloplasty catheter 500, and out the distal port 41 in the distal end thereof. A supporting coil 42 may be provided in the distal portion of the first inner lumen 40 to prevent the catheter shaft 39 from kinking and to enhance radial rigidity and to maintain the transverse dimensions of first inner lumen 40 as the catheter 10 is advanced through the aortic arch. It is particularly important to maintain the roundness of first inner lumen 40 where an endovascular device is to be introduced through the first inner lumen. If the shaft is made of sufficient diameter to accommodate such tools through lumen 40, the shaft may tend to flatten or kink when advanced into the curved region of the aortic arch. The use of wire braid or coil 42 to maintain lumen roundness allows the endovascular device profile to be maximized and allows endovascular devices to be advanced through the lumen with minimum interference. Wire braid or coil 42 may be formed of stainless steel or other biocompatible material such as a cobalt alloy, nickel titanium alloy, aramid fibers such as Kevlarâ„¢ (DuPont), or nylon. The shaft 39 is also provided with a second inner lumen 43 which is in fluid communication with the interior of the occluding balloon 11.
  • Turning now to Figs. 2-4, several additional exemplary embodiments of an endovascular device for partitioning the ascending aorta according to the invention will be described. As illustrated in Fig. 2A, partitioning device 320 includes a shaft 322 having a distal end 324 and a proximal end 326. An expandable means 328 for occluding the ascending aorta is mounted to shaft 322 near distal end 324. In a preferred embodiment, occluding means 328 comprises a polymeric balloon 330 (shown inflated) of a material, geometry, and dimensions suitable for completely occluding the ascending aorta to block systolic and diastolic blood flow, as described more fully below.
  • Shaft 322 has a diameter suitable for introduction through a femoral or iliac artery, usually less than about 9 mm. The length of shaft 322 is preferably greater than about 80 cm, usually about 90-100 cm, so as to position balloon 330 in the ascending aorta between the coronary ostia and the brachiocephalic artery with proximal end 326 disposed outside of the body, preferably from the femoral or iliac artery in the groin area. Alternatively, the shaft may be configured for introduction through the carotid artery, through the brachial artery, or through a penetration in the aorta itself, wherein the shaft may have a length in the range of 20 to 60 cm.
  • Partitioning device 320 further includes a first inner lumen 329, extending between proximal end 326 and distal end 324 with an opening 331 at distal end 324. Additional openings in communication with inner lumen 329 may be provided on a lateral side of shaft 322 near distal end 324.
  • Shaft 322 has a shaped distal portion 332 configured to conform generally to the curvature of the aortic arch such that opening 331 at distal end 324 is spaced apart from the interior wall of the aorta and is axially aligned with the center of the aortic valve. Usually, shaped distal portion 332 will be generally U-shaped, such that a distal segment 334 is disposed at an angle between 135° and 225°, and preferably at approximately 180° relative to an axial direction defined by the generally straight proximal segment 336 of shaft 322. Shaped distal portion 332 will usually have a radius of curvature in the range of 20-80 mm (measured at the radial center of shaft 322), depending upon the size of the aorta in which the device is used. The configuration of shaped distal portion 332 allows distal segment 334 to be positioned centrally within the lumen of the ascending aorta and distal end 324 to be axially aligned with the center of the aortic valve, thereby facilitating infusion or aspiration of fluids as well as introduction of surgical tools through opening 331 without interference with the wall of the aorta, as described more fully below.
  • In an exemplary embodiment, shaped distal portion 332 is preshaped so as to maintain a permanent, generally U-shaped configuration in an unstressed condition. Such a preshaped configuration may be formed by positioning a mandrel having the desired shape in first inner lumen 329, then baking or otherwise heating shaft 322 and the mandrel for a sufficient time and sufficient temperature to create a permanent set therein, e.g., 1-3 hours at a temperature in a range of 120°C to 180°C, depending upon the material used for shaft 322.
  • In alternative embodiments, the U-shaped distal portion 332, rather than having a continuous, constant curvature, may be preshaped in a more angular fashion, with bends of relatively small curvature separating segments which are either straight or of larger curvature. The bends and/or segments may further be configured to engage the inner wall of the aortic arch to deflect distal end into a desired position in the ascending aorta. Alternatively, shaped distal portion may be configured in a general "S" shape for introduction into the ascending aorta from a location superior to the aortic arch. In this way, distal segment may be positioned within the ascending aorta, with proximal segment extending from the aortic arch through the brachiocephalic artery to the carotid or brachial artery, or through a penetration in the aorta itself, to a point outside of the thoracic cavity.
  • As shown in Fig. 2B, distal segment 334 may be skewed (non-coplanar) relative to a central longitudinal axis of proximal segment 336, in order to further conform to the shape of the patient's aortic arch and align with the center of the aortic valve. In an exemplary embodiment, distal segment 334 is disposed at an angle a relative to a plane containing the central axis of proximal portion 336, wherein a is between 2° and 30°, usually between 10° and 20°, and preferably about 15°. The shape and dimensions of shaped distal portion 332 and angle a of distal segment 334 may vary, however, according to the configuration of the aortic arch in any individual patient.
  • In a preferred embodiment, the device will include a soft tip 338 attached to distal end 324 to reduce the risk of damaging cardiac tissue, particularly the leaflets of the aortic valve, in the event the device contacts such tissue. Soft tip 338 may be straight or tapered in the distal direction, with an axial passage aligned with opening 331 at the distal end of shaft 322. Preferably, soft tip 338 will be a low durometer polymer such as polyurethane or Pebax, with a durometer in the range of 65 Shore A to 35 Shore D.
  • At least one radiopaque stripe or marker 339 is preferably provided on shaft 322 near distal end 324 to facilitate fluoroscopic visualization for positioning balloon 330 in the ascending aorta. Radiopaque marker 339 may comprise a band of platinum or other radiopaque material. Alternatively, a filler of barium or bismuth salt may be added to the polymer used for shaft 322 or soft tip 338 to provide radiopacity.
  • As illustrated in Fig. 2A, a straightening element 340 is disposed in first inner lumen 329 of shaft 322 so as to slide longitudinally relative to the shaft. Straightening element 340 may comprise a tubular stylet with a longitudinal passage 344 for receiving a guidewire 342 , as described below. Alternatively, element 340 may comprise a relatively stiff portion of the guidewire itself. Straightening element 340 may be a polymeric material or a biocompatible metal such as stainless steel or nickel titanium alloy with a bending stiffness greater than that of shaft 322. In this way, straightening element 340 may be advanced distally into preshaped distal portion 332 so as to straighten shaft 322, facilitating subcutaneous introduction of partitioning device 320 into an artery and advancement to the aortic arch. Straightening element 340 may then be retracted proximally relative to the shaft so that distal end 324 can be positioned in the ascending aorta with preshaped distal portion 332 conforming to the shape of the aortic arch.
  • A movable guidewire 342 is slidably disposed through first inner lumen 329, either through longitudinal passage 344 in straightening element 340, external and parallel to straightening element 340, or through a separate lumen in shaft 322. Guidewire 342 extends through opening 331 in distal end 324 of shaft 322 and may be advanced into an artery distal to shaft 322, facilitating advancement of shaft 322 through the artery to the ascending aorta by sliding the shaft over the guidewire. In an exemplary embodiment, guidewire 342 is relatively stiff so as to at least partially straighten shaft 322, so that straightening element 340 is unnecessary for introduction of shaft 322. In this embodiment, guidewire 342 may be, for example, stainless steel or a nickel titanium alloy with a diameter of about 1.0 mm to 1.6 mm.
  • Shaft 322 may have any of a variety of configurations depending upon the particular procedure to be performed. In one embodiment, shaft 322 has a multi-lumen configuration with three non-coaxial parallel lumens in a single extrusion, as illustrated in Fig. 2C. The three lumens include first inner lumen 329, which receives straightening element 340 and guidewire 342 and includes opening 331 at its distal end, an inflation lumen 346 which opens at an inflation orifice 347 near the distal end of shaft 322 in communication with the interior of balloon 330, and a third lumen 348 which has an opening (not shown) at distal end 324 of the shaft to sense pressure in the ascending aorta upstream of balloon 330. In this embodiment, the largest transverse dimension of first inner lumen 329 is preferably about 1 mm-4 mm. Advantageously, the distal opening in third lumen 348 is radially offset from opening 331 in first inner lumen 329, so that infusion or aspiration of fluid through first inner lumen 329 will not affect pressure measurements taken through third lumen 348.
  • It should be noted that where partitioning device 320 is to be utilized for antegrade delivery of cardioplegic fluid through first inner lumen 329, it will be configured to provide a sufficient flowrate of such fluid to maintain paralysis of the heart, while avoiding undue hemolysis in the blood component (if any) of the fluid. In a presently preferred embodiment, cold blood cardioplegia is the preferred technique for arresting the heart, wherein a cooled mixture of blood and a crystalloid KCl/saline solution is introduced into the coronary arteries to perfuse and paralyze the myocardium. The cardioplegic fluid mixture is preferably run through tubing immersed in an ice bath so as to cool the fluid to a temperature of about 3°C - 10°C prior to delivery through inner lumen 329. The cardioplegic fluid is delivered through inner lumen 329 at a sufficient flowrate and pressure to maintain a pressure in the aortic root (as measured through third lumen 348) high enough to induce flow through the coronary arteries to perfuse the myocardium. Usually, a pressure of about 6.7 - 13.3 kPa (50-100 mmHg), preferably 8.0 - 9.3 kPa (60-70 mmHg), is maintained in the aortic root during infusion of cardioplegic fluid, although this may vary somewhat depending on patient anatomy, physiological changes such as coronary dilation, and other factors. At the same time, in pumping the cardioplegic fluid through inner lumen 329, it should not be subject to pump pressures greater than about 40 kPa (300 mmHg), so as to avoid hemolysis in the blood component of the fluid mixture. In an exemplary embodiment, first inner lumen 329 is configured to facilitate delivery of the cardioplegic fluid at a rate of about 250-350 ml/min. preferably about 300 ml/min., under a pressure of no more than about 300 ml/min, enabling the delivery of about 500-1000 ml of fluid in 1-3 minutes. To provide the desired flowrate at this pressure, inner lumen 329 usually has a cross-sectional area of at least about 4.5 mm2, and preferably about 5.6-5.9 mm2. In an exemplary embodiment, D-shaped lumen 329 in Fig. 2C has a straight wall about 3.3 mm in width, and a round wall with a radius of about 1.65 mm. A completely circular lumen 329 (not pictured), could have an inner diameter of about 2.7 mm. Inner lumen 329 could be significantly smaller, however, if the cardioplegic fluid did not have a blood component so that it could be delivered under higher pressures without risk of hemolysis. Because of its myocardial protective aspects, however, the aforementioned blood/KCl mixture is presently preferred, requiring a somewhat larger lumen size than would be required for a crystalloid KCl cardioplegic fluid without blood.
  • Shaft 322 may be constructed of any of a variety of materials, including biocompatible polymers such as polyurethane, polyvinyl chloride, polyether block amide, or polyethylene. In a preferred embodiment of the device shown in Fig. 2A, shaft 322 is urethane with a shore durometer in the range of 50D-100D. Shaft 322 may have a bending modulus in the range of 70 to 100 kpsi, preferably about 80-90 kpsi. A bending modulus in this range provides sufficient stiffness to optimize pushability from a femoral or iliac artery to the ascending aorta, while providing sufficient flexibility to navigate the tortuous iliac artery and the aortic arch. Once partitioning device 320 has been positioned with distal end 324 in the ascending aorta, this bending modulus also facilitates exertion of a distally-directed force on shaft 322 from proximal end 326 to maintain the position of balloon 330 against the outflow of blood from the left ventricle as the balloon is inflated. In other embodiments, the dimensions, geometry and/or materials of shaft 322, as well as coil 360, may be varied over the length of the shaft so that the shaft exhibits variable bending stiffness in various regions. For example, preshaped distal portion 332 may be more flexible for tracking through the aortic arch, whereas proximal portion 336 may be stiffer for pushability and resistance to displacement.
  • Balloon 330 may be constructed of various materials and in various geometries. In a preferred embodiment, balloon 330 has a collapsed profile small enough for introduction into the femoral or iliac artery, e.g. 4-9 mm outside diameter, and an expanded (inflated) profile large enough to completely occlude the ascending aorta, e.g. 20-40 mm outside diameter. The ratio of expanded profile diameter to collapsed profile diameter will thus be between 2 and 10, and preferably between 5 and 10. The balloon is further configured to maximize contact of the working surface of the balloon with the aortic wall to resist displacement and to minimize leakage around the balloon, preferably having a working surface with an axial length in the range of about 3 cm to about 7 cm when the balloon is expanded. Textural features such as ribs, ridges or bumps may also be provided on the balloon working surface for increased frictional effects to further resist displacement.
  • Balloon 330 preferably has some degree of radial expansion or elongation so that a single balloon size may be used for aortas of various diameters. Materials which may be used for balloon 330 include polyurethanes, polyethylene terephthalate (PET), polyvinyl chloride (PVC), polyolefin, latex, ethylene vinyl acetate (EVA) and the like. However, balloon 330 must have sufficient structural integrity when inflated to maintain its general shape and position relative to shaft 322 under the systolic pressure of blood flow through the ascending aorta. In an exemplary embodiment, balloon 330 is constructed of polyurethane or a blend of polyurethane and polyvinyl such as PVC. It has been found that such materials have sufficient elastic elongation to accommodate a range of vessel diameters, while having sufficient structural integrity to maintain their shape and position in the ascending aorta when subject to outflow of blood from the left ventricle. In other preferred embodiments, balloon may be further provided with a plurality of folds or pleats which allow the balloon to be collapsed by evacuation to a small collapsed profile for introduction into a femoral or iliac artery.
  • Fig. 2D illustrates the deflated and inflated profile of one preferred embodiment of the elastomeric balloon 330 of the endoaortic partitioning catheter 320. The deflated profile 330' has an oblong or football shape which is imparted by the balloon molding process. The wall thickness of the molded balloon 330' in its deflated state is typically about 0.090-0.130 mm. The deflated balloon 330' has a diameter of approximately 12 mm. The inflated balloon 330 assumes a roughly spherical shape with a maximum diameter of approximately 40 mm when inflated. The football shape of the molded balloon has been shown to be advantageous in that the deflated balloon 330' has a deflated profile which is less bulky and smoother than for other balloon geometries tested. This allows the deflated balloon 330' to be folded and more easily inserted through a percutaneous puncture into the femoral artery or through an introducer sheath or a dual arterial cannula/introducer sheath. Other acceptable geometries for the molded elastomeric balloon 330 include a simple cylinder, an enlarged cylinder with tapered ends or a spherical shape.
  • Fig. 2E illustrates another preferred embodiment of the elastomeric balloon 330 of the endoaortic partitioning catheter 320. After molding, the distal end 200 of the deflated balloon 300' is inverted and adhesively attached to the distal end 202 of the catheter shaft 322. When the balloon is inflated to its inflated profile 330, the distal end 202 of the catheter shaft 322 is protected by the inflated balloon 330 and prevented from touching the aortic valve or the aortic walls, obviating the need for the soft tip 338 of the embodiment of Figs. 2A, 2B and 2D.
  • Referring again to Fig. 2A, a triple-arm adapter 364 is attached to the proximal end 326 of shaft 322. Triple-arm adapter 364 includes a working port 366 in communication with first inner lumen 329 through which straightening element 340 and guidewire 342, may be introduced, to straighten the shaft 322 to facilitate introduction of the catheter 320 into the femoral artery. Once the catheter is positioned within the ascending aorta of the patient, the straightening element 340 and guidewire 342 may be withdrawn to allow introduction of an endovascular device through the working port 366 into the first inner lumen 329 of the catheter. Working port 366 may also be adapted for infusion of fluid such as cardioplegic fluid, saline or contrast solution, as well as for aspiration of blood, fluids and debris through first inner lumen 329. Triple-arm adapter 364 further includes an inflation port 368 in communication with the inflation lumen and configured for connection to an inflation fluid delivery device such as a syringe 370 or other commercially available balloon-inflation device such as the Indeflatorâ„¢ available from Advanced Cardiovascular Systems, Inc. of Santa Clara, CA. A pressure measurement port 372 is in communication with the third lumen (348 or 354) and is adapted for connection to a pressure measurement device. Alternatively, where shaft 322 includes only first inner lumen 329 and inflation lumen 358 as in Figures 26B, 28 and 30, port 372 may be in communication with first inner lumen 329 and configured for pressure measurement, fluid infusion or aspiration.
  • A second alternative embodiment of partitioning device 320 is illustrated in Figs. 3A-3B. In this embodiment, shaft 322 is positionable in an interior lumen 420 of a guiding catheter 422. Device 320 may be configured as described above in reference to Fig. 2A, including balloon 330 near distal end 324, inner lumen 329, inflation lumen 346, pressure lumen 348, soft tip 338 attached to distal end 324, and triple-arm adapter 364 attached to proximal end 326. Guiding catheter 422 has a proximal end 424 and a distal end 426, with axial lumen 420 extending therebetween. A soft tip (not shown) may be attached to distal end 426 to minimize injury to the aorta or aortic valve in the event of contact therewith. A proximal adapter 428 is attached to proximal end 424, and has a first port 430 in communication with lumen 420 through which shaft 322 may be introduced, and a second port 432 in communication with lumen 420 for infusing or aspirating fluid. Port 430 may further include a hemostasis valve. Guiding catheter 422 also has a distal portion 434 which is either preshaped or deflectable into a shape generally conforming to the shape of the aortic arch. Techniques suitable for preshaping or deflecting distal portion 434 of guiding catheter 422 are described above in connection with Figs. 2A and 2B In an exemplary embodiment, guiding catheter 422 is preshaped in a generally U-shaped configuration, with a radius of curvature in the range of 20-80 mm. In this embodiment, a stylet (not shown) like that described above in connection with Figures 25-30 is provided for straightening distal portion 434 for purposes of percutaneously introducing guiding catheter 422 into an artery.
  • In use, guiding catheter 422 is introduced into an artery, e.g. a femoral or iliac artery, and advanced toward the heart until distal end 426 is in the ascending aorta. A guidewire (not shown) may be used to enhance tracking. Where a stylet is used to straighten a preshaped guiding catheter for subcutaneous introduction, the stylet is withdrawn as preshaped distal portion 434 is advanced through the aortic arch. Once guiding catheter 422 is in position, shaft 322 may be introduced through port 430 and lumen 420 and advanced toward the heart until balloon 330 is disposed between the coronary ostia and the brachiocephalic artery, distal to the distal end 426 of guiding catheter 422. The distal portion 332 of shaft 322 is shaped to conform to the aortic arch by preshaped portion 434 of guiding catheter 422. Balloon 330 is then inflated to fully occlude the ascending aorta and block blood flow therethrough.
  • In a third embodiment, shown in Figs. 4A-4B, partitioning device 320 includes a shaping element 440 positionable in a lumen in shaft 322, such as third inner lumen 348. Shaping element 440 has a proximal end 442, a distal end 444 and a preshaped distal portion 446. Preshaped distal portion 446 may be generally U-shaped as illustrated, or may have an angular, "S"-shaped or other configuration in an unstressed condition, which will shape distal portion 332 to generally conform to at least a portion of the patient's aortic arch. Shaping element 440 is preferably stainless steel, nickel titanium alloy, or other biocompatible material with a bending stiffness greater than that of shaft 322 so as to deflect distal portion 332 into the desired shape. Shaping element 440 may be a guidewire over which shaft 322 is advanced to the ascending aorta, or a stylet which is inserted into third inner lumen 348 after shaft 322 is positioned with balloon 330 in the ascending aorta. In a preferred embodiment, shaping element 440 is configured to position distal end 324 of shaft 322 in a radial position within the ascending aorta to be spaced apart from the interior wall thereof, and in particular, axially aligned with the center of the aortic valve.
  • In a further aspect of the invention, illustrated in Figs. 5A-5D partitioning device 320 is coupled to an arterial bypass cannula 450 so as to allow both device 320 and cannula 450 to be introduced through the same arterial puncture. Arterial bypass cannula 450 is configured for connection to a cardiopulmonary bypass system for delivering oxygenated blood to the patient's arterial system. Arterial bypass cannula 450 has a distal end 452, a proximal end 454, a blood flow lumen 456 extending between proximal end 454 and distal end 452, and an outflow port 458 at distal end 452. A plurality of additional outflow ports 460 may be provided along the length of arterial bypass cannula 450, particularly near distal end 452. In a preferred embodiment, arterial bypass cannula 450 has a length between about 10 cm and 60 cm, and preferably between about 15 cm and 30 cm.
  • An adaptor 462 is connected to proximal end 454 of bypass cannula 450, and includes a first access port 464 and a second access port 466, both in fluid communication with blood flow lumen 456. Access port 466 is configured for fluid connection to tubing from a cardiopulmonary bypass system, and preferably has a barbed fitting 468. Access port 464 is configured to receive partitioning device 320 therethrough. Preferably, a hemostasis valve 470, shown in Figs. 5C and 5E, is mounted in access port 464 to prevent leakage of blood and other fluids through access port 464 whether or not shaft 322 of partitioning device 320 is positioned therein. Hemostasis valve 470 may have any number of well-known constructions, including, for example, an elastomeric disk 469 having one or more slits 472 through which shaft 422 may be positioned, and a diaphragm 471 adjacent to the disk with a central hole 474 for sealing around the periphery of shaft 322. A hemostasis valve of this type is described in U.S. Patent No. 4,000,739. Other types of hemostasis valves may also be used, such as duck-bill valves, O-ring seals, and rotational or sliding mechanical valves. In addition, a Touhy-Borst valve 473 including a threaded, rotatable cap 475 may be provided on the proximal end of access port 464 to facilitate clamping and sealing around shaft 322 by tightening cap 475, which compresses O-rings 477 about shaft 322.
  • Shaft 322 of partitioning device 320 and blood flow lumen 456 of bypass cannula 450 are configured and dimensioned to facilitate sufficient blood flow through blood flow lumen 456 to support full cardiopulmonary bypass with complete cessation of cardiac activity, without an undesirable level of hemolysis. In a preferred embodiment, arterial bypass cannula 450 has an outer diameter of 6 mm to 10 mm, and blood flow lumen 456 has an inner diameter of 5 mm to 9 mm. Shaft 322 of partitioning device 320 has an outer diameter in the range of 2 mm to 5 mm. In this way, blood flow lumen 456, with shaft 322 positioned therein, facilitates a blood flow rate of at least about 4 liters/minute at a pump pressure of less than about 33.3 kPa (250 mmHg).
  • Arterial bypass cannula 450 is preferably introduced into an artery, usually a femoral artery, with partitioning device 320 removed from blood flow lumen 456. An obturator 476, illustrated in Fig. 5D, may be positioned in blood flow lumen 456 such that the tapered distal end 478 of obturator 476 extends distally from the distal end 452 of arterial bypass cannula 450. The arterial bypass cannula 450 may be introduced into the artery by various techniques including percutaneous methods such as the Seldinger technique, but is usually of sufficient size to require a surgical cutdown. A guidewire 480 may be slidably positioned through a lumen 482 in obturator 476 to facilitate introduction of arterial bypass cannula 450. Guidewire 480 is advanced into the artery through an arteriotomy, and arterial bypass cannula 450 with obturator 476 positioned therein is advanced into the artery over guidewire 480. Obturator 476 may then be removed, allowing partitioning device 320 to be introduced into the artery through blood flow lumen 456, usually over guidewire 480. Guidewire 480 may be advanced toward the heart and into the ascending aorta to facilitate positioning the distal end 324 of partitioning device 320 therein.
  • In one particularly preferred embodiment, which is shown in cross section in Fig. 5B, the shaft 322 of partitioning device 320 has an outer diameter of approximately 3.45 mm or 10.5 French (Charrière scale). The three lumen shaft 320 is extruded from a thermoplastic elastomer with a Shore D durometer of approximately 72. The D-shaped infusion lumen 329 has a height from the interlumen wall 702 to the exterior wall 700 of approximately 2.08 mm which allows sufficient flow rate for delivery of cardioplegic fluid and provides sufficient diametrical clearance for passage of an endovascular device through the infusion lumen 329 for performing an endovascular procedure within the heart or blood vessels of the patient. The balloon inflation lumen 346 in this embodiment has a width of approximately 1.40 mm, and the pressure monitoring lumen 348 has a width of approximately 0.79 mm. The interlumen wall 702 between the three lumens and the exterior wall 700 of the shaft 322 have a wall thickness of approximately 0.20 mm. When the 10.5 French shaft 322 is introduced through the blood flow lumen 456 of a 21 French (7.00 mm outer diameter) arterial bypass cannula 450, the blood flow lumen 456 allows a blood flow rate of approximately 5 liters/minute at a pump pressure of about 46.7 kPa (350 mmHg). When the 10.5 French shaft 322 is introduced through the blood flow lumen 456 of a 23 French (7.67 mm outer diameter) arterial bypass cannula 450, the blood flow lumen 456 allows a blood flow rate of approximately 6 liters/minute at a pump pressure of about 46.7 kPa 350 mmHg. The choice of what size arterial bypass cannula 450 to use for a given patient will depend on the size of the patient's femoral arteries and overall body size which determines the flow rate required.
  • In an alternative embodiment, arterial bypass cannula 450 may be configured so that partitioning device 320 is not removable from blood flow lumen 456. In this embodiment, bypass cannula 450 is introduced into an artery with partitioning device 320 positioned in blood flow lumen 456. Partitioning device 320 may be slidable within a limited range of movement within blood flow lumen 456. Alternatively, partitioning device 320 may be fixed to arterial bypass cannula 450 to prevent relative movement between the two. For example, shaft 322 may be extruded from the same tubing which is used to form arterial bypass cannula 450. Or, shaft 322 may be attached within the interior of blood flow lumen 456 or at the distal end 452 of arterial bypass cannula 450. Additionally, distal end 452 of bypass cannula 450 may be tapered to seal around shaft 322 and may or may not be bonded to shaft 322. In this configuration, side ports 460 permit outflow of blood from blood flow lumen 456.
  • Fig. 6 shows a schematic representation of a patient's heart 210 partly cut-away to show some of the internal structures of the heart. The endoaortic partitioning device 212 has been percutaneously introduced into an artery, such as the femoral artery, by the Seldinger technique or an arterial cutdown and advanced into the ascending aorta 223. The occlusion balloon 227 is inflated within the ascending aorta 223 to occlude the aortic lumen and to separate the heart 210 and the aortic root 226 from the remainder of the circulatory system. Generally, the circulatory system is placed on cardiopulmonary bypass and the heart is stopped, as by infusion of a cardioplegic agent or by hypothermic arrest or other means, simultaneous with the inflation of the occlusion balloon 227. One or more endovascular devices are introduced through an internal lumen in the endoaortic partitioning device 212 to perform a diagnostic or therapeutic endovascular procedure within the heart or blood vessels of the patient.
  • In this illustrative example which is outside the scope of the present invention, a fiberoptic cardioscope or angioscope 237 has been introduced through the endoaortic partitioning device 212 into the aortic root 226 for visualizing the internal structures of the heart 210 and the blood vessels. The aortic root 226 and/or the chambers of the heart 210 and its blood vessels can be filled with a transparent liquid, for example saline solution or crystaloid cardioplegic solution, infused through a lumen the endoaortic partitioning device 212 to displace the blood and provide a clear view of structures such as the aortic or mitral valve, the aortic root or the coronary arteries. The angioscope 237 can be used for diagnosis of insufficient, stenotic or calcified heart valves, atrial or ventricular septal defects, patent ductus arteriosus, coronary artery disease or other conditions. This endovascular prodedure may be performed in preparation for or for observation during a therapeutic procedure such as repair or replacement of a heart valve or as an adjunct to a concomitant procedure on the heart. In addition, Fig. 6 shows a left ventricular venting catheter 238 introduced into left ventricle of the heart 210 to vent blood and other fluids from the heart to relieve pressure that could cause distention of the heart while the patient is on cardiopulmonary bypass.
  • Figs. 1 and 7 show another embodiment of the system for performing endovascular procedures of the present invention. The endoaortic partitioning device 10 has previously been introduced into the ascending aorta 12 and the occlusion balloon 11 inflated to occlude the aortic lumen, as described above. In this illustrative example which is outside the scope of the invention, a valvuloplasty catheter 500 has been introduced through an internal lumen 40 of the endoaortic partitioning device 10, as shown in Fig. 1. The valvuloplasty catheter 500 has an expandable dilatation balloon 502 on the distal end of an elongated shaft 504. A fluid-filled syringe 508 or other inflation device is attached to a fitting 506 on the proximal end of the shaft 504. An inflation lumen within the shaft 504 connects the fitting 506 with the interior of the dilatation balloon 502. The dilatation balloon 502 is introduced through the lumen 40 of the endoaortic partitioning device 10 in a deflated condition until the dilatation balloon 502 emerges from the distal end 41 of the endoaortic partitioning device 10 into the aortic root. The dilatation balloon 502 is advanced across the patient's aortic valve 66 and the dilatation balloon 502 is expanded within the aortic valve 66, as shown in Fig. 7, to relieve a stenosis of the valve or to mobilize calcified valve leaflets. The dilatation balloon 502 is then deflated and the valvuloplasty catheter 500 is withdrawn from the patient.
  • Fig. 8 shows an exemplary embodiment of the system of the present invention that combines an electrophysiology mapping and ablation catheter 660 with the endoaortic partitioning device previously described. Fig. 8 shows a schematic representation of the left side of a patient's heart cut away to show the interior of the left ventricle 13 and left atrium 14. The endoaortic partitioning device 10 has been percutaneously introduced into the ascending aorta 12 and the occlusion balloon 11 may be inflated to occlude the aortic lumen and to separate the heart and the aortic root from the remainder of the circulatory system. A multi-electrode endocardial electrophysiology mapping and ablation catheter 660 is introduced through an internal lumen 40 of the endoaortic partitioning device 10. In Fig. 8 the electrophysiology catheter 660 has been advanced through the aortic valve 66 and into the left ventricle 13 of the heart.
  • The electrophysiology catheter 660 has four wire assemblies 662 that extend through an elongated catheter shaft 666. Each of the wire assemblies 662 has multiple electrodes 664, six per wire assembly in this illustrative example, which are each connected to separate insulated electrical wires (not shown) within the catheter shaft 666. Separate electrical connectors (not shown) are connected to each of the electrical wires on the proximal end of the catheter 660. The wire assemblies 662 are compressible so that they can be withdrawn into an internal lumen 668 within the catheter shaft 666 for introduction of the device 660 through the endoaortic partitioning device 10. When extended from the catheter shaft 666, the wire assemblies 662 expand within the left ventricle 13 of the heart to hold the electrodes 664 in electrical contact with the interior wall of the ventricle 13. The electrophysiology catheter 660 can likewise be advanced through the mitral valve 520 and expanded in the left atrium 14 of the heart.
  • The electrophysiology catheter 660 can be used to map the electrically conductive pathways in the ventricular wall and to locate any abnormal foci that could result in atrial or ventricular tachycardia or other electrophysiological problems of the heart. Once the abnormal foci have been localized they can be ablated by applying a direct or alternating current across the two closest adjoining electrodes to the site sufficient to permanently disrupt the flow of electrical impulses along that path. Alternatively, another ablation catheter may be used to localize and ablate the abnormal foci once they have been diagnosed. Specific examples of electrophysiology mapping and ablation catheters suitable for use with the system for performing endovascular procedures of the present invention are described in the following patents; U.S. patent 4,699,147 granted to Donald A. Chilson and Kevin W. Smith, U.S. patent 5,327,889 granted to Mir A. Imran, U.S. patent 4,960,134 granted to Wilton W. Webster, U.S. patent 5,140,987 granted to Claudio Schuger and Russell T. Steinman, U.S. patent 4,522,212 granted to Sandra 1. Gelinas, Daniel G. Cerundolo and john A. Abele, U.S. patent 4,660,571 granted to Stanley R. Hess and Terri Kovacs, U.S. patent 4,664,120 granted to Stanley R. Hess, U.S. patent 5,125,896 granted to Hikmat J. Hojeibane, and U.S. patent 5,104,393 granted to Jeffrey M. Isner and Richard Clarke.
  • In the above examples, the system for performing endovascular procedures of the present invention can be operated in a variety of different operating modes depending on the nature and circumstances of the endovascular procedure to be performed. In many cases it will be desirable to combine an endovascular procedure with another surgical procedure on the heart performed using either a thoracoscopic or a standard open chest approach. In these cases, either or both of the endovascular procedure and the surgical procedure may be performed while the patient's circulatory system is supported by a cardiopulmonary bypass system. Also, if desired, the endoaortic occlusion balloon of the endoaortic partitioning catheter may be inflated to isolate the patient's heart and a cardioplegic agent infused through the endoaortic partitioning catheter to stop the patient's heart while performing the endovascular procedure and/or the surgical procedure. In some cases it will be desirable to perform the endovascular procedure while the heart is still beating and to only stop the heart for all or a part of the surgical procedure, or vice versa, in order to reduce the overall clamp time. The endovascular procedure and the surgical procedure may be performed simultaneously or serially in either order. One example of this operating mode discussed above is the combination of angioplasty, atherectomy or endarterectomy with CABG surgery in order to realize a more complete revascularization of the patient's heart.
  • In other cases, one or more endovascular procedures may be performed on the patient's heart without combining them with another surgical procedure. This mode of operation will be advantageous when it is desirable to stop the heart to facilitate performing the endovascular procedure or to relieve the stress on the heart during a high risk interventional procedure. This may allow the application of various endovascular procedures to patients whose cardiac function is highly compromised and therefore might not otherwise be good candidates for the procedure.
  • In an alternate mode of operation the endoaortic partitioning catheter can be used as a guiding catheter for introducing an endovascular device and for performing an endovascular procedure while the patient is on partial cardiopulmonary support without inflating the occlusion balloon or inducing cardiac arrest. If and when it is desired, the endoaortic partitioning catheter can be activated to occlude the aorta and induce cardioplegia, thereby converting the patient from partial cardiopulmonary support to full cardiopulmonary bypass. This mode of operation would be advantageous when it was desired to follow the endovascular procedure with another surgical procedure on the heart using either a thoracoscopic or standard open chest approach. It would also be advantageous when performing a high risk interventional procedure so that, in the event of complications, the patient can be immediately placed on full cardiopulmonary bypass and prepared for emergency surgery without delay.
  • In each of these operating modes, the system for performing endovascular procedures built in accordance with the present invention provides a number of advantages heretofore unknown. Particularly, it allows a compatible combination of devices for performing endovascular procedures with the capability of performing complete cardioplumonary bypass and cardioplegic arrest for myocardial preservation. It also allows the combination of one or more endovascular procedures with surgical procedures on the heart or blood vessels in a manner that facilitates both types of procedures and reduces the invasiveness of the procedures, thereby reducing the trauma and morbidity to the patient as a result.
  • While the present invention has been described herein in terms of certain preferred embodiments, it will be apparent to one of ordinary skill in the art that many modifications and improvements can be made to the invention without departing from the scope thereof.

Claims (16)

  1. A system for inducing cardioplegic arrest and performing an endovascular procedure within the heart, comprising:
    a) an elongated endovascular device for performing the endovascular procedure, having proximal and distal ends; and
    b) an elongated aortic catheter (10,212,330) adapted to be advanced to a location within a patient's ascending aorta (12,223), having proximal and distal ends, having an expandable member (11,227,330)on a distal portion thereof which when expanded within the patient's ascending aorta occludes the passageway therethrough between the coronary ostia and the brachiocaphalic artery, and having at least one lumen (40)connecting a proximal port at said proximal end of said catheter with a distal port to said expandable member, said lumen (40) being configured to allow said endovascular device to be slidably positioned therein with said distal end of said endovascular device extending distally from said distal port, and the expandable member when expanded positioning the distal port so that the device extends therefrom for performing the procedure within the heart,
       characterised in that said device comprises
       an electrophysiological mapping and ablation catheter (660) for performing an electrophysiological mapping and/or ablation of the heart of said patient, said electrophysiology catheter being configured to be slidably positioned within said lumen (40) of said aortic catheter (10).
  2. The system of claim 1, further comprising:
    c) a cardiopulmonary by-pass system (94) including means to withdraw blood from a venous system of the patient, means to oxygenate the withdrawn blood and means to direct the oxygenated blood into the arterial system of the patient.
  3. The system of claim 2, further comprising:
    d) a means for infusing a cardioplegic agent through said elongated aortic catheter (10,212,320) into a coronary vasculature of said patient.
  4. The system of claim 2, further comprising:
    e) a means for infusing a cardioplegic agent retrograde into a coronary vasculature of said patient.
  5. The system of claim 1, wherein said expandable member (11,227,330) of said aortic catheter comprises an inflatable balloon fluidly connected to an inflation lumen extending from said inflatable balloon to an inflation port at said proximal end of said aortic catheter.
  6. The system of claim 1, wherein said aortic catheter comprises a flexible shaft having a preshaped distal portion configured to conform generally to the patient's aortic arch and a means for straightening said distal portion of the shaft to facilitate introducing the shaft into an artery downstream of the patient's ascending aorta.
  7. The system of claim 6, wherein the preshaped distal portion of the shaft is generally U-shaped in an unstressed condition to facilitate positioning the shaft from an arterial location downstream of the patient's aortic arch.
  8. The system of claim 6, wherein the preshaped distal portion of the shaft is generally S-shaped in an unstressed condition to facilitate positioning the shaft from an arterial location superior to the patient's aortic arch.
  9. The system of claim 6, wherein the preshaped distal portion of the shaft has a radius of curvature in the range of 20 to 80 mm.
  10. The system of claim 6, wherein the preshaped distal portion has a distal segment for positioning in the ascending aorta and a proximal segment for positioning in the descending aorta, the distal segment being skewed relative to the proximal segment.
  11. The system of claim 1, wherein said aortic catheter comprises a shaft having a length of at least 80 cm to facilitate transluminal positioning from a femoral artery to the ascending aorta.
  12. The system of claim 1, wherein said lumen of said aortic catheter has a diameter of at least about 2 mm to facilitate positioning said endovascular device therethrough.
  13. The system of claim 1, wherein said aortic catheter comprises a flexible shaft having a preshaped distal portion configured to engage a coronary ostium of the patient.
  14. The system of claim 1, wherein said aortic catheter comprises a pressure monitoring lumen connecting a proximal pressure monitoring port at said proximal end of said catheter with a distal pressure monitoring port distal to said expandable member.
  15. The system of claim 1, wherein said aortic catheter comprises a pressure monitoring lumen connecting a proximal pressure monitoring port at said proximal end of said catheter with a distal pressure monitoring port distal to said expandable member.
  16. The system of claim 1, further comprising a hemostasis valve means at said proximal port of said aortic catheter for allowing said endovascular device to be introduced into said lumen of said aortic catheter without loss of fluid.
EP96908744A 1995-03-30 1996-03-11 System for performing endovascular procedures Expired - Lifetime EP0819013B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41536695A 1995-03-30 1995-03-30
US415366 1995-03-30
PCT/US1996/003266 WO1996030072A1 (en) 1995-03-30 1996-03-11 System and methods for performing endovascular procedures

Publications (3)

Publication Number Publication Date
EP0819013A1 EP0819013A1 (en) 1998-01-21
EP0819013A4 EP0819013A4 (en) 1998-12-23
EP0819013B1 true EP0819013B1 (en) 2004-06-23

Family

ID=23645401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96908744A Expired - Lifetime EP0819013B1 (en) 1995-03-30 1996-03-11 System for performing endovascular procedures

Country Status (6)

Country Link
EP (1) EP0819013B1 (en)
AT (1) ATE269742T1 (en)
AU (1) AU708976B2 (en)
CA (1) CA2215970A1 (en)
DE (1) DE69632776T2 (en)
WO (1) WO1996030072A1 (en)

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682390B2 (en) 2001-07-31 2010-03-23 Medtronic, Inc. Assembly for setting a valve prosthesis in a corporeal duct
US7712606B2 (en) 2005-09-13 2010-05-11 Sadra Medical, Inc. Two-part package for medical implant
US7748389B2 (en) 2003-12-23 2010-07-06 Sadra Medical, Inc. Leaflet engagement elements and methods for use thereof
US7780726B2 (en) 2001-07-04 2010-08-24 Medtronic, Inc. Assembly for placing a prosthetic valve in a duct in the body
US7780725B2 (en) 2004-06-16 2010-08-24 Sadra Medical, Inc. Everting heart valve
US7824443B2 (en) 2003-12-23 2010-11-02 Sadra Medical, Inc. Medical implant delivery and deployment tool
US7824442B2 (en) 2003-12-23 2010-11-02 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US7871436B2 (en) 2007-02-16 2011-01-18 Medtronic, Inc. Replacement prosthetic heart valves and methods of implantation
US7892281B2 (en) 1999-11-17 2011-02-22 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US7914569B2 (en) 2005-05-13 2011-03-29 Medtronics Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US7959666B2 (en) 2003-12-23 2011-06-14 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US7959672B2 (en) 2003-12-23 2011-06-14 Sadra Medical Replacement valve and anchor
US7988724B2 (en) 2003-12-23 2011-08-02 Sadra Medical, Inc. Systems and methods for delivering a medical implant
US8016877B2 (en) 1999-11-17 2011-09-13 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8048153B2 (en) 2003-12-23 2011-11-01 Sadra Medical, Inc. Low profile heart valve and delivery system
US8052749B2 (en) 2003-12-23 2011-11-08 Sadra Medical, Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US8052750B2 (en) 2006-09-19 2011-11-08 Medtronic Ventor Technologies Ltd Valve prosthesis fixation techniques using sandwiching
US8075615B2 (en) 2006-03-28 2011-12-13 Medtronic, Inc. Prosthetic cardiac valve formed from pericardium material and methods of making same
US8231670B2 (en) 2003-12-23 2012-07-31 Sadra Medical, Inc. Repositionable heart valve and method
US8241274B2 (en) 2000-01-19 2012-08-14 Medtronic, Inc. Method for guiding a medical device
US8246678B2 (en) 2003-12-23 2012-08-21 Sadra Medicl, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8252052B2 (en) 2003-12-23 2012-08-28 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8287584B2 (en) 2005-11-14 2012-10-16 Sadra Medical, Inc. Medical implant deployment tool
US8313525B2 (en) 2008-03-18 2012-11-20 Medtronic Ventor Technologies, Ltd. Valve suturing and implantation procedures
US8312825B2 (en) 2008-04-23 2012-11-20 Medtronic, Inc. Methods and apparatuses for assembly of a pericardial prosthetic heart valve
US8328868B2 (en) 2004-11-05 2012-12-11 Sadra Medical, Inc. Medical devices and delivery systems for delivering medical devices
US8343213B2 (en) 2003-12-23 2013-01-01 Sadra Medical, Inc. Leaflet engagement elements and methods for use thereof
US8506620B2 (en) 2005-09-26 2013-08-13 Medtronic, Inc. Prosthetic cardiac and venous valves
US8562672B2 (en) 2004-11-19 2013-10-22 Medtronic, Inc. Apparatus for treatment of cardiac valves and method of its manufacture
US8579962B2 (en) 2003-12-23 2013-11-12 Sadra Medical, Inc. Methods and apparatus for performing valvuloplasty
US8579966B2 (en) 1999-11-17 2013-11-12 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8591570B2 (en) 2004-09-07 2013-11-26 Medtronic, Inc. Prosthetic heart valve for replacing previously implanted heart valve
US8603160B2 (en) 2003-12-23 2013-12-10 Sadra Medical, Inc. Method of using a retrievable heart valve anchor with a sheath
US8613765B2 (en) 2008-02-28 2013-12-24 Medtronic, Inc. Prosthetic heart valve systems
US8628566B2 (en) 2008-01-24 2014-01-14 Medtronic, Inc. Stents for prosthetic heart valves
US8652204B2 (en) 2010-04-01 2014-02-18 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US8696743B2 (en) 2008-04-23 2014-04-15 Medtronic, Inc. Tissue attachment devices and methods for prosthetic heart valves
US8721714B2 (en) 2008-09-17 2014-05-13 Medtronic Corevalve Llc Delivery system for deployment of medical devices
US8728155B2 (en) 2011-03-21 2014-05-20 Cephea Valve Technologies, Inc. Disk-based valve apparatus and method for the treatment of valve dysfunction
US8834564B2 (en) 2006-09-19 2014-09-16 Medtronic, Inc. Sinus-engaging valve fixation member
US8840663B2 (en) 2003-12-23 2014-09-23 Sadra Medical, Inc. Repositionable heart valve method
US8858619B2 (en) 2002-04-23 2014-10-14 Medtronic, Inc. System and method for implanting a replacement valve
US8870948B1 (en) 2013-07-17 2014-10-28 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US8940014B2 (en) 2011-11-15 2015-01-27 Boston Scientific Scimed, Inc. Bond between components of a medical device
US8951243B2 (en) 2011-12-03 2015-02-10 Boston Scientific Scimed, Inc. Medical device handle
US8986361B2 (en) 2008-10-17 2015-03-24 Medtronic Corevalve, Inc. Delivery system for deployment of medical devices
US8998976B2 (en) 2011-07-12 2015-04-07 Boston Scientific Scimed, Inc. Coupling system for medical devices
US9005273B2 (en) 2003-12-23 2015-04-14 Sadra Medical, Inc. Assessing the location and performance of replacement heart valves
US9011521B2 (en) 2003-12-23 2015-04-21 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US9078781B2 (en) 2006-01-11 2015-07-14 Medtronic, Inc. Sterile cover for compressible stents used in percutaneous device delivery systems
US9089422B2 (en) 2008-01-24 2015-07-28 Medtronic, Inc. Markers for prosthetic heart valves
US9131926B2 (en) 2011-11-10 2015-09-15 Boston Scientific Scimed, Inc. Direct connect flush system
US9277993B2 (en) 2011-12-20 2016-03-08 Boston Scientific Scimed, Inc. Medical device delivery systems
US9333100B2 (en) 2008-01-24 2016-05-10 Medtronic, Inc. Stents for prosthetic heart valves
US9439757B2 (en) 2014-12-09 2016-09-13 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US9510945B2 (en) 2011-12-20 2016-12-06 Boston Scientific Scimed Inc. Medical device handle
US9526609B2 (en) 2003-12-23 2016-12-27 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US9788942B2 (en) 2015-02-03 2017-10-17 Boston Scientific Scimed Inc. Prosthetic heart valve having tubular seal
US20170325938A1 (en) 2016-05-16 2017-11-16 Boston Scientific Scimed, Inc. Replacement heart valve implant with invertible leaflets
US9861477B2 (en) 2015-01-26 2018-01-09 Boston Scientific Scimed Inc. Prosthetic heart valve square leaflet-leaflet stitch
US9901445B2 (en) 2014-11-21 2018-02-27 Boston Scientific Scimed, Inc. Valve locking mechanism
US10080652B2 (en) 2015-03-13 2018-09-25 Boston Scientific Scimed, Inc. Prosthetic heart valve having an improved tubular seal
US10136991B2 (en) 2015-08-12 2018-11-27 Boston Scientific Scimed Inc. Replacement heart valve implant
US10143552B2 (en) 2015-05-14 2018-12-04 Cephea Valve Technologies, Inc. Replacement mitral valves
US10172708B2 (en) 2012-01-25 2019-01-08 Boston Scientific Scimed, Inc. Valve assembly with a bioabsorbable gasket and a replaceable valve implant
US10179041B2 (en) 2015-08-12 2019-01-15 Boston Scientific Scimed Icn. Pinless release mechanism
US10195392B2 (en) 2015-07-02 2019-02-05 Boston Scientific Scimed, Inc. Clip-on catheter
US10201418B2 (en) 2010-09-10 2019-02-12 Symetis, SA Valve replacement devices, delivery device for a valve replacement device and method of production of a valve replacement device
US10201417B2 (en) 2015-02-03 2019-02-12 Boston Scientific Scimed Inc. Prosthetic heart valve having tubular seal
US10258465B2 (en) 2003-12-23 2019-04-16 Boston Scientific Scimed Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US10278805B2 (en) 2000-08-18 2019-05-07 Atritech, Inc. Expandable implant devices for filtering blood flow from atrial appendages
US10285809B2 (en) 2015-03-06 2019-05-14 Boston Scientific Scimed Inc. TAVI anchoring assist device
US10299922B2 (en) 2005-12-22 2019-05-28 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US10470881B2 (en) 2015-05-14 2019-11-12 Cephea Valve Technologies, Inc. Replacement mitral valves
US10555809B2 (en) 2012-06-19 2020-02-11 Boston Scientific Scimed, Inc. Replacement heart valve
US10583005B2 (en) 2016-05-13 2020-03-10 Boston Scientific Scimed, Inc. Medical device handle
US10779940B2 (en) 2015-09-03 2020-09-22 Boston Scientific Scimed, Inc. Medical device handle
US10828154B2 (en) 2017-06-08 2020-11-10 Boston Scientific Scimed, Inc. Heart valve implant commissure support structure
US10849746B2 (en) 2015-05-14 2020-12-01 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
US10898325B2 (en) 2017-08-01 2021-01-26 Boston Scientific Scimed, Inc. Medical implant locking mechanism
US10939996B2 (en) 2017-08-16 2021-03-09 Boston Scientific Scimed, Inc. Replacement heart valve commissure assembly
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11090158B2 (en) 2017-01-23 2021-08-17 Cephea Valve Technologies, Inc. Replacement mitral valves
US11147668B2 (en) 2018-02-07 2021-10-19 Boston Scientific Scimed, Inc. Medical device delivery system with alignment feature
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11191641B2 (en) 2018-01-19 2021-12-07 Boston Scientific Scimed, Inc. Inductance mode deployment sensors for transcatheter valve system
US11229517B2 (en) 2018-05-15 2022-01-25 Boston Scientific Scimed, Inc. Replacement heart valve commissure assembly
US11241310B2 (en) 2018-06-13 2022-02-08 Boston Scientific Scimed, Inc. Replacement heart valve delivery device
US11241312B2 (en) 2018-12-10 2022-02-08 Boston Scientific Scimed, Inc. Medical device delivery system including a resistance member
US11246625B2 (en) 2018-01-19 2022-02-15 Boston Scientific Scimed, Inc. Medical device delivery system with feedback loop
US11278398B2 (en) 2003-12-23 2022-03-22 Boston Scientific Scimed, Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US11285002B2 (en) 2003-12-23 2022-03-29 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a heart valve
US11331187B2 (en) 2016-06-17 2022-05-17 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US11439504B2 (en) 2019-05-10 2022-09-13 Boston Scientific Scimed, Inc. Replacement heart valve with improved cusp washout and reduced loading
US11439732B2 (en) 2018-02-26 2022-09-13 Boston Scientific Scimed, Inc. Embedded radiopaque marker in adaptive seal
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US11730595B2 (en) 2015-07-02 2023-08-22 Boston Scientific Scimed, Inc. Adjustable nosecone
US11771544B2 (en) 2011-05-05 2023-10-03 Symetis Sa Method and apparatus for compressing/loading stent-valves

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251104B1 (en) 1995-05-10 2001-06-26 Eclipse Surgical Technologies, Inc. Guiding catheter system for ablating heart tissue
US6322548B1 (en) 1995-05-10 2001-11-27 Eclipse Surgical Technologies Delivery catheter system for heart chamber
AU5168398A (en) * 1996-11-07 1998-05-29 Vascular Science Inc. Steerable instrument for use in medical procedures
US6132397A (en) * 1997-05-01 2000-10-17 Chase Medical Inc. Integral aortic arch infusion clamp catheter
US6068608A (en) * 1997-05-01 2000-05-30 Chase Medical, Inc. Method of using integral aortic arch infusion clamp
US6241699B1 (en) 1998-07-22 2001-06-05 Chase Medical, Inc. Catheter system and method for posterior epicardial revascularization and intracardiac surgery on a beating heart
FR2768324B1 (en) 1997-09-12 1999-12-10 Jacques Seguin SURGICAL INSTRUMENT FOR PERCUTANEOUSLY FIXING TWO AREAS OF SOFT TISSUE, NORMALLY MUTUALLY REMOTE, TO ONE ANOTHER
US6706010B1 (en) * 1997-10-08 2004-03-16 Kaneka Corporation Balloon catheter and method of production thereof
US6159178A (en) 1998-01-23 2000-12-12 Heartport, Inc. Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested
IL138667A0 (en) * 1998-03-31 2001-10-31 Transvascular Inc Tissue penetrating catheters having integral imaging transducers and methods of their use
EP0979635A2 (en) 1998-08-12 2000-02-16 Origin Medsystems, Inc. Tissue dissector apparatus
US7666204B2 (en) 1999-04-09 2010-02-23 Evalve, Inc. Multi-catheter steerable guiding system and methods of use
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US7811296B2 (en) 1999-04-09 2010-10-12 Evalve, Inc. Fixation devices for variation in engagement of tissue
US8216256B2 (en) 1999-04-09 2012-07-10 Evalve, Inc. Detachment mechanism for implantable fixation devices
DE60045429D1 (en) 1999-04-09 2011-02-03 Evalve Inc Device for heart valve surgery
US20040044350A1 (en) 1999-04-09 2004-03-04 Evalve, Inc. Steerable access sheath and methods of use
US6558313B1 (en) 2000-11-17 2003-05-06 Embro Corporation Vein harvesting system and method
US10667823B2 (en) 2003-05-19 2020-06-02 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US20060004323A1 (en) 2004-04-21 2006-01-05 Exploramed Nc1, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
AU2005244903B2 (en) 2004-05-14 2010-11-04 Evalve, Inc. Locking mechanisms for fixation devices and methods of engaging tissue
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
US7635329B2 (en) 2004-09-27 2009-12-22 Evalve, Inc. Methods and devices for tissue grasping and assessment
US7962208B2 (en) 2005-04-25 2011-06-14 Cardiac Pacemakers, Inc. Method and apparatus for pacing during revascularization
US9770230B2 (en) 2006-06-01 2017-09-26 Maquet Cardiovascular Llc Endoscopic vessel harvesting system components
US11304800B2 (en) 2006-09-19 2022-04-19 Medtronic Ventor Technologies Ltd. Sinus-engaging valve fixation member
US20080125849A1 (en) * 2006-11-13 2008-05-29 Janet Burpee Delivery system catheter with rotating distal end
US8945177B2 (en) 2011-09-13 2015-02-03 Abbott Cardiovascular Systems Inc. Gripper pusher mechanism for tissue apposition systems
US9572666B2 (en) 2014-03-17 2017-02-21 Evalve, Inc. Mitral valve fixation device removal devices and methods
US10390943B2 (en) 2014-03-17 2019-08-27 Evalve, Inc. Double orifice device for transcatheter mitral valve replacement
US10188392B2 (en) 2014-12-19 2019-01-29 Abbott Cardiovascular Systems, Inc. Grasping for tissue repair
WO2016115375A1 (en) 2015-01-16 2016-07-21 Boston Scientific Scimed, Inc. Displacement based lock and release mechanism
US10426617B2 (en) 2015-03-06 2019-10-01 Boston Scientific Scimed, Inc. Low profile valve locking mechanism and commissure assembly
US10524912B2 (en) 2015-04-02 2020-01-07 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
US10376673B2 (en) 2015-06-19 2019-08-13 Evalve, Inc. Catheter guiding system and methods
US10238494B2 (en) 2015-06-29 2019-03-26 Evalve, Inc. Self-aligning radiopaque ring
US10667815B2 (en) 2015-07-21 2020-06-02 Evalve, Inc. Tissue grasping devices and related methods
US10413408B2 (en) 2015-08-06 2019-09-17 Evalve, Inc. Delivery catheter systems, methods, and devices
CA2995193C (en) * 2015-08-12 2023-11-07 TDL Innovations, LLC Steerable aspiration catheter system
US10238495B2 (en) 2015-10-09 2019-03-26 Evalve, Inc. Delivery catheter handle and methods of use
US10342660B2 (en) 2016-02-02 2019-07-09 Boston Scientific Inc. Tensioned sheathing aids
US10245136B2 (en) 2016-05-13 2019-04-02 Boston Scientific Scimed Inc. Containment vessel with implant sheathing guide
US11510796B2 (en) 2016-06-03 2022-11-29 Fundacion Cardioinfantil Horseshoe-shaped guide catheter and procedure for ductus arteriosus angioplasty in newborn and infant patients
US10736632B2 (en) 2016-07-06 2020-08-11 Evalve, Inc. Methods and devices for valve clip excision
US11071564B2 (en) 2016-10-05 2021-07-27 Evalve, Inc. Cardiac valve cutting device
US10363138B2 (en) 2016-11-09 2019-07-30 Evalve, Inc. Devices for adjusting the curvature of cardiac valve structures
US10398553B2 (en) 2016-11-11 2019-09-03 Evalve, Inc. Opposing disk device for grasping cardiac valve tissue
US10426616B2 (en) 2016-11-17 2019-10-01 Evalve, Inc. Cardiac implant delivery system
US10779837B2 (en) 2016-12-08 2020-09-22 Evalve, Inc. Adjustable arm device for grasping tissues
US10314586B2 (en) 2016-12-13 2019-06-11 Evalve, Inc. Rotatable device and method for fixing tricuspid valve tissue
US11065119B2 (en) 2017-05-12 2021-07-20 Evalve, Inc. Long arm valve repair clip
US20210307892A1 (en) * 2019-09-18 2021-10-07 Daniel Ezra Walzman Carotid stent incorporating arch fulcrum catheters and flow reversal
CA3157491A1 (en) * 2019-11-06 2021-05-14 Mg Stroke Analytics Inc. Stent and catheter systems for treatment of unstable plaque and cerebral aneurysm
WO2023015272A1 (en) * 2021-08-05 2023-02-09 Pedersen Wesley Robert Double lumen pigtail catheter and hocm gradient catheter

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4660571A (en) * 1985-07-18 1987-04-28 Cordis Corporation Percutaneous lead having radially adjustable electrode
US4794931A (en) * 1986-02-28 1989-01-03 Cardiovascular Imaging Systems, Inc. Catheter apparatus, system and method for intravascular two-dimensional ultrasonography
US4781681A (en) * 1987-09-15 1988-11-01 Gv Medical, Inc. Inflatable tip for laser catheterization
JPH01207078A (en) * 1988-02-15 1989-08-21 Terumo Corp Catheter tube and endoscope
US4924863A (en) * 1988-05-04 1990-05-15 Mmtc, Inc. Angioplastic method for removing plaque from a vas
US5011469A (en) * 1988-08-29 1991-04-30 Shiley, Inc. Peripheral cardiopulmonary bypass and coronary reperfusion system
AU6376190A (en) * 1989-10-25 1991-05-02 C.R. Bard Inc. Occluding catheter and methods for treating cerebral arteries
US5330451A (en) * 1992-12-17 1994-07-19 Shelhigh, Inc. Multi purpose perfusion cannula
AU685161B2 (en) * 1993-09-17 1998-01-15 Edwards Lifesciences Ag Endovascular system for arresting the heart

Cited By (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892281B2 (en) 1999-11-17 2011-02-22 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8579966B2 (en) 1999-11-17 2013-11-12 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US9066799B2 (en) 1999-11-17 2015-06-30 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8016877B2 (en) 1999-11-17 2011-09-13 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US9060856B2 (en) 1999-11-17 2015-06-23 Medtronic Corevalve Llc Transcatheter heart valves
US8986329B2 (en) 1999-11-17 2015-03-24 Medtronic Corevalve Llc Methods for transluminal delivery of prosthetic valves
US8876896B2 (en) 1999-11-17 2014-11-04 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8998979B2 (en) 1999-11-17 2015-04-07 Medtronic Corevalve Llc Transcatheter heart valves
US10219901B2 (en) 1999-11-17 2019-03-05 Medtronic CV Luxembourg S.a.r.l. Prosthetic valve for transluminal delivery
US8241274B2 (en) 2000-01-19 2012-08-14 Medtronic, Inc. Method for guiding a medical device
US10278805B2 (en) 2000-08-18 2019-05-07 Atritech, Inc. Expandable implant devices for filtering blood flow from atrial appendages
US8002826B2 (en) 2001-07-04 2011-08-23 Medtronic Corevalve Llc Assembly for placing a prosthetic valve in a duct in the body
US8628570B2 (en) 2001-07-04 2014-01-14 Medtronic Corevalve Llc Assembly for placing a prosthetic valve in a duct in the body
US9149357B2 (en) 2001-07-04 2015-10-06 Medtronic CV Luxembourg S.a.r.l. Heart valve assemblies
US7780726B2 (en) 2001-07-04 2010-08-24 Medtronic, Inc. Assembly for placing a prosthetic valve in a duct in the body
US7682390B2 (en) 2001-07-31 2010-03-23 Medtronic, Inc. Assembly for setting a valve prosthesis in a corporeal duct
US8858619B2 (en) 2002-04-23 2014-10-14 Medtronic, Inc. System and method for implanting a replacement valve
US9526609B2 (en) 2003-12-23 2016-12-27 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8623076B2 (en) 2003-12-23 2014-01-07 Sadra Medical, Inc. Low profile heart valve and delivery system
US9585750B2 (en) 2003-12-23 2017-03-07 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8182528B2 (en) 2003-12-23 2012-05-22 Sadra Medical, Inc. Locking heart valve anchor
US8231670B2 (en) 2003-12-23 2012-07-31 Sadra Medical, Inc. Repositionable heart valve and method
US8052749B2 (en) 2003-12-23 2011-11-08 Sadra Medical, Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US8246678B2 (en) 2003-12-23 2012-08-21 Sadra Medicl, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8252052B2 (en) 2003-12-23 2012-08-28 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US9585749B2 (en) 2003-12-23 2017-03-07 Boston Scientific Scimed, Inc. Replacement heart valve assembly
US10314695B2 (en) 2003-12-23 2019-06-11 Boston Scientific Scimed Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US10335273B2 (en) 2003-12-23 2019-07-02 Boston Scientific Scimed Inc. Leaflet engagement elements and methods for use thereof
US10478289B2 (en) 2003-12-23 2019-11-19 Boston Scientific Scimed, Inc. Replacement valve and anchor
US8343213B2 (en) 2003-12-23 2013-01-01 Sadra Medical, Inc. Leaflet engagement elements and methods for use thereof
US9532872B2 (en) 2003-12-23 2017-01-03 Boston Scientific Scimed, Inc. Systems and methods for delivering a medical implant
US8048153B2 (en) 2003-12-23 2011-11-01 Sadra Medical, Inc. Low profile heart valve and delivery system
US11285002B2 (en) 2003-12-23 2022-03-29 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a heart valve
US10716663B2 (en) 2003-12-23 2020-07-21 Boston Scientific Scimed, Inc. Methods and apparatus for performing valvuloplasty
US10772724B2 (en) 2003-12-23 2020-09-15 Boston Scientific Scimed, Inc. Medical devices and delivery systems for delivering medical devices
US9393113B2 (en) 2003-12-23 2016-07-19 Boston Scientific Scimed Inc. Retrievable heart valve anchor and method
US8579962B2 (en) 2003-12-23 2013-11-12 Sadra Medical, Inc. Methods and apparatus for performing valvuloplasty
US7988724B2 (en) 2003-12-23 2011-08-02 Sadra Medical, Inc. Systems and methods for delivering a medical implant
US9387076B2 (en) 2003-12-23 2016-07-12 Boston Scientific Scimed Inc. Medical devices and delivery systems for delivering medical devices
US8603160B2 (en) 2003-12-23 2013-12-10 Sadra Medical, Inc. Method of using a retrievable heart valve anchor with a sheath
US10925724B2 (en) 2003-12-23 2021-02-23 Boston Scientific Scimed, Inc. Replacement valve and anchor
US9358106B2 (en) 2003-12-23 2016-06-07 Boston Scientific Scimed Inc. Methods and apparatus for performing valvuloplasty
US10258465B2 (en) 2003-12-23 2019-04-16 Boston Scientific Scimed Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US8623078B2 (en) 2003-12-23 2014-01-07 Sadra Medical, Inc. Replacement valve and anchor
US9358110B2 (en) 2003-12-23 2016-06-07 Boston Scientific Scimed, Inc. Medical devices and delivery systems for delivering medical devices
US7959672B2 (en) 2003-12-23 2011-06-14 Sadra Medical Replacement valve and anchor
US11696825B2 (en) 2003-12-23 2023-07-11 Boston Scientific Scimed, Inc. Replacement valve and anchor
US9320599B2 (en) 2003-12-23 2016-04-26 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a heart valve
US9308085B2 (en) 2003-12-23 2016-04-12 Boston Scientific Scimed, Inc. Repositionable heart valve and method
US9277991B2 (en) 2003-12-23 2016-03-08 Boston Scientific Scimed, Inc. Low profile heart valve and delivery system
US7959666B2 (en) 2003-12-23 2011-06-14 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US9872768B2 (en) 2003-12-23 2018-01-23 Boston Scientific Scimed, Inc. Medical devices and delivery systems for delivering medical devices
US7824442B2 (en) 2003-12-23 2010-11-02 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US9011521B2 (en) 2003-12-23 2015-04-21 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8828078B2 (en) 2003-12-23 2014-09-09 Sadra Medical, Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US9005273B2 (en) 2003-12-23 2015-04-14 Sadra Medical, Inc. Assessing the location and performance of replacement heart valves
US8840662B2 (en) 2003-12-23 2014-09-23 Sadra Medical, Inc. Repositionable heart valve and method
US8840663B2 (en) 2003-12-23 2014-09-23 Sadra Medical, Inc. Repositionable heart valve method
US7824443B2 (en) 2003-12-23 2010-11-02 Sadra Medical, Inc. Medical implant delivery and deployment tool
US8858620B2 (en) 2003-12-23 2014-10-14 Sadra Medical Inc. Methods and apparatus for endovascularly replacing a heart valve
US10206774B2 (en) 2003-12-23 2019-02-19 Boston Scientific Scimed Inc. Low profile heart valve and delivery system
US11185408B2 (en) 2003-12-23 2021-11-30 Boston Scientific Scimed, Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US7748389B2 (en) 2003-12-23 2010-07-06 Sadra Medical, Inc. Leaflet engagement elements and methods for use thereof
US9956075B2 (en) 2003-12-23 2018-05-01 Boston Scientific Scimed Inc. Methods and apparatus for endovascularly replacing a heart valve
US8894703B2 (en) 2003-12-23 2014-11-25 Sadra Medical, Inc. Systems and methods for delivering a medical implant
US11278398B2 (en) 2003-12-23 2022-03-22 Boston Scientific Scimed, Inc. Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US8951299B2 (en) 2003-12-23 2015-02-10 Sadra Medical, Inc. Medical devices and delivery systems for delivering medical devices
US11484405B2 (en) 2004-06-16 2022-11-01 Boston Scientific Scimed, Inc. Everting heart valve
US7780725B2 (en) 2004-06-16 2010-08-24 Sadra Medical, Inc. Everting heart valve
US8992608B2 (en) 2004-06-16 2015-03-31 Sadra Medical, Inc. Everting heart valve
US8668733B2 (en) 2004-06-16 2014-03-11 Sadra Medical, Inc. Everting heart valve
US9744035B2 (en) 2004-06-16 2017-08-29 Boston Scientific Scimed, Inc. Everting heart valve
US8591570B2 (en) 2004-09-07 2013-11-26 Medtronic, Inc. Prosthetic heart valve for replacing previously implanted heart valve
US8617236B2 (en) 2004-11-05 2013-12-31 Sadra Medical, Inc. Medical devices and delivery systems for delivering medical devices
US8328868B2 (en) 2004-11-05 2012-12-11 Sadra Medical, Inc. Medical devices and delivery systems for delivering medical devices
US10531952B2 (en) 2004-11-05 2020-01-14 Boston Scientific Scimed, Inc. Medical devices and delivery systems for delivering medical devices
US9498329B2 (en) 2004-11-19 2016-11-22 Medtronic, Inc. Apparatus for treatment of cardiac valves and method of its manufacture
US8562672B2 (en) 2004-11-19 2013-10-22 Medtronic, Inc. Apparatus for treatment of cardiac valves and method of its manufacture
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US7914569B2 (en) 2005-05-13 2011-03-29 Medtronics Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US9504564B2 (en) 2005-05-13 2016-11-29 Medtronic Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US9060857B2 (en) 2005-05-13 2015-06-23 Medtronic Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US8136659B2 (en) 2005-09-13 2012-03-20 Sadra Medical, Inc. Two-part package for medical implant
US7712606B2 (en) 2005-09-13 2010-05-11 Sadra Medical, Inc. Two-part package for medical implant
US8506620B2 (en) 2005-09-26 2013-08-13 Medtronic, Inc. Prosthetic cardiac and venous valves
US8287584B2 (en) 2005-11-14 2012-10-16 Sadra Medical, Inc. Medical implant deployment tool
US10299922B2 (en) 2005-12-22 2019-05-28 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US10314701B2 (en) 2005-12-22 2019-06-11 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US9078781B2 (en) 2006-01-11 2015-07-14 Medtronic, Inc. Sterile cover for compressible stents used in percutaneous device delivery systems
US10058421B2 (en) 2006-03-28 2018-08-28 Medtronic, Inc. Prosthetic cardiac valve formed from pericardium material and methods of making same
US9331328B2 (en) 2006-03-28 2016-05-03 Medtronic, Inc. Prosthetic cardiac valve from pericardium material and methods of making same
US8075615B2 (en) 2006-03-28 2011-12-13 Medtronic, Inc. Prosthetic cardiac valve formed from pericardium material and methods of making same
US8348996B2 (en) 2006-09-19 2013-01-08 Medtronic Ventor Technologies Ltd. Valve prosthesis implantation techniques
US8834564B2 (en) 2006-09-19 2014-09-16 Medtronic, Inc. Sinus-engaging valve fixation member
US10004601B2 (en) 2006-09-19 2018-06-26 Medtronic Ventor Technologies Ltd. Valve prosthesis fixation techniques using sandwiching
US8876894B2 (en) 2006-09-19 2014-11-04 Medtronic Ventor Technologies Ltd. Leaflet-sensitive valve fixation member
US8876895B2 (en) 2006-09-19 2014-11-04 Medtronic Ventor Technologies Ltd. Valve fixation member having engagement arms
US8052750B2 (en) 2006-09-19 2011-11-08 Medtronic Ventor Technologies Ltd Valve prosthesis fixation techniques using sandwiching
US8747460B2 (en) 2006-09-19 2014-06-10 Medtronic Ventor Technologies Ltd. Methods for implanting a valve prothesis
US8771345B2 (en) 2006-09-19 2014-07-08 Medtronic Ventor Technologies Ltd. Valve prosthesis fixation techniques using sandwiching
US8414643B2 (en) 2006-09-19 2013-04-09 Medtronic Ventor Technologies Ltd. Sinus-engaging valve fixation member
US8348995B2 (en) 2006-09-19 2013-01-08 Medtronic Ventor Technologies, Ltd. Axial-force fixation member for valve
US10195033B2 (en) 2006-09-19 2019-02-05 Medtronic Ventor Technologies Ltd. Valve prosthesis fixation techniques using sandwiching
US8771346B2 (en) 2006-09-19 2014-07-08 Medtronic Ventor Technologies Ltd. Valve prosthetic fixation techniques using sandwiching
US9642704B2 (en) 2006-09-19 2017-05-09 Medtronic Ventor Technologies Ltd. Catheter for implanting a valve prosthesis
US9138312B2 (en) 2006-09-19 2015-09-22 Medtronic Ventor Technologies Ltd. Valve prostheses
US7871436B2 (en) 2007-02-16 2011-01-18 Medtronic, Inc. Replacement prosthetic heart valves and methods of implantation
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US9089422B2 (en) 2008-01-24 2015-07-28 Medtronic, Inc. Markers for prosthetic heart valves
US8628566B2 (en) 2008-01-24 2014-01-14 Medtronic, Inc. Stents for prosthetic heart valves
US9333100B2 (en) 2008-01-24 2016-05-10 Medtronic, Inc. Stents for prosthetic heart valves
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11154398B2 (en) 2008-02-26 2021-10-26 JenaValve Technology. Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8613765B2 (en) 2008-02-28 2013-12-24 Medtronic, Inc. Prosthetic heart valve systems
US8961593B2 (en) 2008-02-28 2015-02-24 Medtronic, Inc. Prosthetic heart valve systems
US9592120B2 (en) 2008-03-18 2017-03-14 Medtronic Ventor Technologies, Ltd. Valve suturing and implantation procedures
US8313525B2 (en) 2008-03-18 2012-11-20 Medtronic Ventor Technologies, Ltd. Valve suturing and implantation procedures
US8312825B2 (en) 2008-04-23 2012-11-20 Medtronic, Inc. Methods and apparatuses for assembly of a pericardial prosthetic heart valve
US8696743B2 (en) 2008-04-23 2014-04-15 Medtronic, Inc. Tissue attachment devices and methods for prosthetic heart valves
US8511244B2 (en) 2008-04-23 2013-08-20 Medtronic, Inc. Methods and apparatuses for assembly of a pericardial prosthetic heart valve
US9532873B2 (en) 2008-09-17 2017-01-03 Medtronic CV Luxembourg S.a.r.l. Methods for deployment of medical devices
US8721714B2 (en) 2008-09-17 2014-05-13 Medtronic Corevalve Llc Delivery system for deployment of medical devices
US10321997B2 (en) 2008-09-17 2019-06-18 Medtronic CV Luxembourg S.a.r.l. Delivery system for deployment of medical devices
US8986361B2 (en) 2008-10-17 2015-03-24 Medtronic Corevalve, Inc. Delivery system for deployment of medical devices
US8652204B2 (en) 2010-04-01 2014-02-18 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US11554010B2 (en) 2010-04-01 2023-01-17 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US10716665B2 (en) 2010-04-01 2020-07-21 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US11833041B2 (en) 2010-04-01 2023-12-05 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US9925044B2 (en) 2010-04-01 2018-03-27 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US10201418B2 (en) 2010-09-10 2019-02-12 Symetis, SA Valve replacement devices, delivery device for a valve replacement device and method of production of a valve replacement device
US10869760B2 (en) 2010-09-10 2020-12-22 Symetis Sa Valve replacement devices, delivery device for a valve replacement device and method of production of a valve replacement device
US8728155B2 (en) 2011-03-21 2014-05-20 Cephea Valve Technologies, Inc. Disk-based valve apparatus and method for the treatment of valve dysfunction
US11771544B2 (en) 2011-05-05 2023-10-03 Symetis Sa Method and apparatus for compressing/loading stent-valves
US8998976B2 (en) 2011-07-12 2015-04-07 Boston Scientific Scimed, Inc. Coupling system for medical devices
US9131926B2 (en) 2011-11-10 2015-09-15 Boston Scientific Scimed, Inc. Direct connect flush system
US9555219B2 (en) 2011-11-10 2017-01-31 Boston Scientific Scimed, Inc. Direct connect flush system
US8940014B2 (en) 2011-11-15 2015-01-27 Boston Scientific Scimed, Inc. Bond between components of a medical device
US10478300B2 (en) 2011-11-15 2019-11-19 Boston Scientific Scimed, Inc. Bond between components of a medical device
US9642705B2 (en) 2011-11-15 2017-05-09 Boston Scientific Scimed Inc. Bond between components of a medical device
US9370421B2 (en) 2011-12-03 2016-06-21 Boston Scientific Scimed, Inc. Medical device handle
US8951243B2 (en) 2011-12-03 2015-02-10 Boston Scientific Scimed, Inc. Medical device handle
US9510945B2 (en) 2011-12-20 2016-12-06 Boston Scientific Scimed Inc. Medical device handle
US9277993B2 (en) 2011-12-20 2016-03-08 Boston Scientific Scimed, Inc. Medical device delivery systems
US10172708B2 (en) 2012-01-25 2019-01-08 Boston Scientific Scimed, Inc. Valve assembly with a bioabsorbable gasket and a replaceable valve implant
US10555809B2 (en) 2012-06-19 2020-02-11 Boston Scientific Scimed, Inc. Replacement heart valve
US11382739B2 (en) 2012-06-19 2022-07-12 Boston Scientific Scimed, Inc. Replacement heart valve
US11510780B2 (en) 2013-07-17 2022-11-29 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US9554899B2 (en) 2013-07-17 2017-01-31 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US9561103B2 (en) 2013-07-17 2017-02-07 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US10624742B2 (en) 2013-07-17 2020-04-21 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US8870948B1 (en) 2013-07-17 2014-10-28 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US10154906B2 (en) 2013-07-17 2018-12-18 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
US10149761B2 (en) 2013-07-17 2018-12-11 Cephea Valve Technlologies, Inc. System and method for cardiac valve repair and replacement
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US9901445B2 (en) 2014-11-21 2018-02-27 Boston Scientific Scimed, Inc. Valve locking mechanism
US10548721B2 (en) 2014-12-09 2020-02-04 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US9492273B2 (en) 2014-12-09 2016-11-15 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US11147665B2 (en) 2014-12-09 2021-10-19 Cepha Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US10869755B2 (en) 2014-12-09 2020-12-22 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US9439757B2 (en) 2014-12-09 2016-09-13 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US9861477B2 (en) 2015-01-26 2018-01-09 Boston Scientific Scimed Inc. Prosthetic heart valve square leaflet-leaflet stitch
US9788942B2 (en) 2015-02-03 2017-10-17 Boston Scientific Scimed Inc. Prosthetic heart valve having tubular seal
US10201417B2 (en) 2015-02-03 2019-02-12 Boston Scientific Scimed Inc. Prosthetic heart valve having tubular seal
US10285809B2 (en) 2015-03-06 2019-05-14 Boston Scientific Scimed Inc. TAVI anchoring assist device
US10080652B2 (en) 2015-03-13 2018-09-25 Boston Scientific Scimed, Inc. Prosthetic heart valve having an improved tubular seal
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US10470881B2 (en) 2015-05-14 2019-11-12 Cephea Valve Technologies, Inc. Replacement mitral valves
US10555808B2 (en) 2015-05-14 2020-02-11 Cephea Valve Technologies, Inc. Replacement mitral valves
US11617646B2 (en) 2015-05-14 2023-04-04 Cephea Valve Technologies, Inc. Replacement mitral valves
US10849746B2 (en) 2015-05-14 2020-12-01 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
US10143552B2 (en) 2015-05-14 2018-12-04 Cephea Valve Technologies, Inc. Replacement mitral valves
US11730595B2 (en) 2015-07-02 2023-08-22 Boston Scientific Scimed, Inc. Adjustable nosecone
US10195392B2 (en) 2015-07-02 2019-02-05 Boston Scientific Scimed, Inc. Clip-on catheter
US10856973B2 (en) 2015-08-12 2020-12-08 Boston Scientific Scimed, Inc. Replacement heart valve implant
US10179041B2 (en) 2015-08-12 2019-01-15 Boston Scientific Scimed Icn. Pinless release mechanism
US10136991B2 (en) 2015-08-12 2018-11-27 Boston Scientific Scimed Inc. Replacement heart valve implant
US10779940B2 (en) 2015-09-03 2020-09-22 Boston Scientific Scimed, Inc. Medical device handle
US11382742B2 (en) 2016-05-13 2022-07-12 Boston Scientific Scimed, Inc. Medical device handle
US10583005B2 (en) 2016-05-13 2020-03-10 Boston Scientific Scimed, Inc. Medical device handle
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US10201416B2 (en) 2016-05-16 2019-02-12 Boston Scientific Scimed, Inc. Replacement heart valve implant with invertible leaflets
US20170325938A1 (en) 2016-05-16 2017-11-16 Boston Scientific Scimed, Inc. Replacement heart valve implant with invertible leaflets
US10709552B2 (en) 2016-05-16 2020-07-14 Boston Scientific Scimed, Inc. Replacement heart valve implant with invertible leaflets
US11331187B2 (en) 2016-06-17 2022-05-17 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
US11090158B2 (en) 2017-01-23 2021-08-17 Cephea Valve Technologies, Inc. Replacement mitral valves
US11058535B2 (en) 2017-01-23 2021-07-13 Cephea Valve Technologies, Inc. Replacement mitral valves
US10568737B2 (en) 2017-01-23 2020-02-25 Cephea Valve Technologies, Inc. Replacement mitral valves
US10828153B2 (en) 2017-01-23 2020-11-10 Cephea Valve Technologies, Inc. Replacement mitral valves
US10828154B2 (en) 2017-06-08 2020-11-10 Boston Scientific Scimed, Inc. Heart valve implant commissure support structure
US10898325B2 (en) 2017-08-01 2021-01-26 Boston Scientific Scimed, Inc. Medical implant locking mechanism
US10939996B2 (en) 2017-08-16 2021-03-09 Boston Scientific Scimed, Inc. Replacement heart valve commissure assembly
US11191641B2 (en) 2018-01-19 2021-12-07 Boston Scientific Scimed, Inc. Inductance mode deployment sensors for transcatheter valve system
US11246625B2 (en) 2018-01-19 2022-02-15 Boston Scientific Scimed, Inc. Medical device delivery system with feedback loop
US11147668B2 (en) 2018-02-07 2021-10-19 Boston Scientific Scimed, Inc. Medical device delivery system with alignment feature
US11439732B2 (en) 2018-02-26 2022-09-13 Boston Scientific Scimed, Inc. Embedded radiopaque marker in adaptive seal
US11229517B2 (en) 2018-05-15 2022-01-25 Boston Scientific Scimed, Inc. Replacement heart valve commissure assembly
US11241310B2 (en) 2018-06-13 2022-02-08 Boston Scientific Scimed, Inc. Replacement heart valve delivery device
US11241312B2 (en) 2018-12-10 2022-02-08 Boston Scientific Scimed, Inc. Medical device delivery system including a resistance member
US11439504B2 (en) 2019-05-10 2022-09-13 Boston Scientific Scimed, Inc. Replacement heart valve with improved cusp washout and reduced loading

Also Published As

Publication number Publication date
EP0819013A1 (en) 1998-01-21
DE69632776T2 (en) 2005-08-25
WO1996030072A1 (en) 1996-10-03
AU5188596A (en) 1996-10-16
ATE269742T1 (en) 2004-07-15
EP0819013A4 (en) 1998-12-23
CA2215970A1 (en) 1996-10-03
AU708976B2 (en) 1999-08-19
DE69632776D1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
EP0819013B1 (en) System for performing endovascular procedures
US6029671A (en) System and methods for performing endovascular procedures
US20060058775A1 (en) System and methods for performing endovascular procedures
EP1129744B1 (en) Cardiopulmonary bypass system for closed-chest intervention
US5792094A (en) Method of delivering cardioplegic fluid to a patient's heart
US5769812A (en) System for cardiac procedures
US6866650B2 (en) System for cardiac procedures
EP0819014B1 (en) Endovascular cardiac venting catheter
EP1208867B1 (en) Endovascular system for arresting the heart
WO1999015227A1 (en) Main stage catheterization instrument
AU740743B2 (en) Cardiopulmonary bypass system for closed-chest intervention
AU1952100A (en) Endovascular cardiac venting catheter and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19981105

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010704

RTI1 Title (correction)

Free format text: SYSTEM FOR PERFORMING ENDOVASCULAR PROCEDURES

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GIFFORD, HANSEN, S., III

Inventor name: STERMAN, WESLEY, D.

Inventor name: PETERS, WILLIAM, S.

Inventor name: STEVENS, JOHN, H.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69632776

Country of ref document: DE

Date of ref document: 20040729

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040923

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040923

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041004

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20080303

Year of fee payment: 13

Ref country code: MC

Payment date: 20080228

Year of fee payment: 13

Ref country code: LU

Payment date: 20080313

Year of fee payment: 13

Ref country code: IT

Payment date: 20080326

Year of fee payment: 13

Ref country code: IE

Payment date: 20080313

Year of fee payment: 13

Ref country code: GB

Payment date: 20080305

Year of fee payment: 13

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080311

Year of fee payment: 13

Ref country code: DE

Payment date: 20080306

Year of fee payment: 13

NLS Nl: assignments of ep-patents

Owner name: EDWARDS LIFESCIENCES AG

Effective date: 20080429

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090311

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20091001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20091130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090311

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090311

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090311